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Bacille Calmette-Guérin (BCG) vaccination is associated with a reduction in all-cause
infant mortality in high mortality settings. The underlying mechanisms remain uncertain
but long-term modulation of the innate immune response (trained immunity) may be
involved.
Methods
Whole blood from 212 neonates enrolled in a randomised trial of neonatal BCG
vaccination was stimulated in vitro with killed pathogens and Toll-like receptor (TLR)
ligands to interrogate cytokine responses.
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Results
BCG-vaccinated infants had increased production of IL-6 in unstimulated samples and
decreased production of IL1-ra, IL-6, and IL-10 and the chemokines MIP-1α, MIP-1ß,
MCP-1 following stimulation with peptidoglycan (TLR2) and R848 (TLR7/8). BCG-
vaccinated infants also had decreased MCP-1 responses following stimulation with
heterologous pathogens. Sex and maternal BCG vaccination status interacted with
neonatal BCG vaccination.
Conclusions
Neonatal BCG vaccination influences cytokine responses to TLR ligands and
heterologous pathogens. This effect is characterised by decreased anti-inflammatory
cytokine and chemokine responses in the context of higher levels of IL-6 in
unstimulated samples. This supports the hypothesis that BCG vaccination modulates
the innate immune system. Further research is warranted to determine if there is an
association between these findings and the beneficial "non-specific" effects of BCG
vaccine on all-cause mortality.
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Background (Words 192) 
Bacille Calmette-Guérin (BCG) vaccination is associated with a reduction in all-cause infant 
mortality in high mortality settings. The underlying mechanisms remain uncertain but long-
term modulation of the innate immune response (trained immunity) may be involved. 
 
Methods 
Whole blood from 212 neonates enrolled in a randomised trial of neonatal BCG vaccination 
was stimulated in vitro with killed pathogens and Toll-like receptor (TLR) ligands to 
interrogate cytokine responses.  
 
Results 
BCG-vaccinated infants had increased production of IL-6 in unstimulated samples and 
decreased production of IL1-ra, IL-6, and IL-10 and the chemokines MIP-1α, MIP-1ß, MCP-1 
following stimulation with peptidoglycan (TLR2) and R848 (TLR7/8). BCG-vaccinated infants 
also had decreased MCP-1 responses following stimulation with heterologous pathogens. 
Sex and maternal BCG vaccination status interacted with neonatal BCG vaccination. 
 
Conclusions 
Neonatal BCG vaccination influences cytokine responses to TLR ligands and heterologous 
pathogens. This effect is characterised by decreased anti-inflammatory cytokine and 
chemokine responses in the context of higher levels of IL-6 in unstimulated samples. This 
supports the hypothesis that BCG vaccination modulates the innate immune system. 
Further research is warranted to determine if there is an association between these findings 
and the beneficial “non-specific” effects of BCG vaccine on all-cause mortality. 
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Background (3459) 
 
Substantial evidence supports the concept that Bacille Calmette-Guérin (BCG) vaccine 
reduces all-cause infant mortality in high mortality settings [1-4]. The recent WHO Special 
Advisory Group of Experts (SAGE) on Immunisation systematic review of the heterologous 
(‘non-specific’) effects of BCG showed that neonatal BCG vaccination is associated with a 
30% reduction in all-cause mortality (RR 0.70 (95% CI 0.49-1.01) [5]. Epidemiological studies 
also suggest that BCG given at birth protects against the development of allergic disease [6, 
7] and pneumonia [8]. 
 
Randomised controlled trials of BCG vaccination at birth report a reduction in neonatal 
mortality attributable to infection [1, 3]. Evidence suggests that the benefit of BCG 
vaccination is conferred as early as 7 days of life [4]. Clinical and demographic factors that 
influence vaccine responses include sex [1, 9], co-administration and timing of other 
neonatal vaccines or supplemental vitamins [10] and maternal BCG vaccination [11]. 
 
The need for further research into the immunological mechanisms underlying the 
heterologous effects of BCG has been highlighted [12]. BCG administration in animal models 
has shown improved survival against a wide range of pathogens including bacteria, viruses 
fungi and parasites [13]. Multiple pathways of innate, cellular and adaptive immunity are 
proposed to underpin BCG’s protective effect [14]. A previous study done in West Africa 
showed that BCG vaccination altered neonatal cytokine responses following stimulation 
with Toll-like receptor (TLR) ligands [15]. Altered responses following BCG vaccination have 
also been reported following in vitro stimulation of peripheral blood mononuclear cells with 
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heterologous bacteria in adults [16]. It is proposed that this results from induction of 
‘trained immunity’ (immune memory in the innate immune system) through epigenetic 
reprogramming of monocytes [16].  
 
Our study aimed to investigate whether BCG vaccination impacts neonatal cytokine 
responses to TLR ligands and clinically significant bacterial and fungal pathogens, and thus 
induces heterologous innate immune effects. 
 
Methods 
 
Participants were a subset of infants recruited from The Melbourne Infant Study: BCG for 
the prevention of allergy and infection (MIS BAIR), a randomised controlled trial of BCG in 
1272 newborn infants with the primary outcomes of allergic sensitisation, eczema and lower 
respiratory tract infection (Clinical trials registration NCT01906853). Participants were 
randomised 1:1 to vaccination with BCG-Denmark 0.05 mL intradermally within 10 days of 
birth or no BCG vaccination. All participants also received a birth dose of hepatitis B vaccine 
as per Australian immunisation guidelines. A subset of 447 participants recruited over an 18-
month period had blood sample for immunological analyses (Figure 1). Exclusion criteria for 
inclusion in the immunological study were: (i) suspected neonatal or maternal sepsis; (ii) 
infant did not receive hepatitis B vaccine prior to blood sampling; or (iii) infant received 
blood products in the first 7 days of life.  
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Written informed consent was obtained from the parents of all participants. The study was 
approved by the human ethics research committees of the Royal Children’s Hospital (HREC 
33025) and the Mercy Hospital for Women (HREC R12/28).  
 
Participants were visited in their home 7 (±4) days after randomisation. Blood was collected 
via a closed loop system into sodium-heparin tubes (S-monovette, Numbrecht, Germany) 
pre-tested for absence of endotoxin. Blood samples were kept at room temperature, 
protected from direct sunlight, and transported to the laboratory and stimulated at 4 hours 
(± 10%; 24 minutes) after collection. Laboratory personnel were blind to the participants’ 
BCG vaccination status. 
 
Whole blood, diluted 1:1 with RPMI-1640 medium (GlutaMAX™ Supplement, HEPES, Gibco, 
Life Technologies), was added to pre-prepared stimulation assay strips (MICROLON™ 600 
Greiner-One 8-well strips). The assay strips were made using a validated robotic system to 
maximise standardisation of stimulant volume, and were stored at –80°C until addition of 
blood. The final stimulant concentrations were BCG-Denmark 75 μg/mL, killed 
Mycobacterium tuberculosis 1.0 x 106 CFU/mL, seven heat-killed bacteria (Escherichia coli 
1.0 x 106 CFU/mL, Haemophilus influenzae type B 1.0 x 106 CFU/mL, Staphylococcus aureus 
1.0 x 107 CFU/mL, Streptococcus agalactiae 1.0 x 107 CFU/mL, Streptococcus pneumoniae 
serotype 15C 1.0 x 107 CFU/mL and Listeria monocytogenes 1.0 x 107 CFU/mL), one fungus 
(Candida albicans 1.0 x 106 CFU/mL) and four TLR ligands (lipopolysaccharide [LPS] 100 
ng/mL, resiquimod [R848] 3.5 μg/mL, peptidoglycan [PEPG] 10 μg/mL and (S)-(2,3-
bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4OH,trihydrochloride 
[Pam3Cysk4] 1 μg/mL (all from Invivogen]) and RPMI. Pathogens were clinical isolates 
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obtained from children with invasive disease at the Royal Children’s Hospital Melbourne, 
Parkville, Australia, and killed by heat-treatment at 70C for 2 hours. Sterility was confirmed 
by the absence of growth in culture medium. Concentrations of all stimuli were optimised in 
preliminary experiments (data not shown). The stimulation assay was incubated at 37°C (5% 
CO2: air) for 20 (± 2) hours.  
 
Supernatants were analysed in batches using Bio-Rad human cytokine kits following the 
manufacturer’s instructions. The mean fluorescence intensity was read for each cytokine 
using an xMAP Luminex 200 Analyser. Each sample was analysed in two separate kits at 
different dilutions to account for the anticipated dynamic range of the cytokine results 
indicated by preliminary experiments (data not shown): (i) sample diluted 1:100 (7-plex): IL-
1β, IL-1ra, IL-6, IL-8, MCP-1 (MCAF), MIP-1α, MIP-1ß, and (ii) sample diluted 1:4 (5-plex): 
IFN-, IL-10, TNF-α, MIF and MIG.  
 
Statistical analysis was done using Stata version 13.1. Cytokine results that were below the 
lower limit of detection were assigned a value of half the lowest detectable value (either the 
lowest standard on the curve or the lowest extrapolated value below this) multiplied by the 
appropriate dilution factor. There were no instances when cytokine results were above the 
upper limit of detection. Prior to analysis, cytokine data were log transformed. 
 
The effect of (i) BCG vaccination, (ii) reported maternal BCG vaccination status and (iii) 
timing of randomisation (early: less than 48 hours after birth; late: 48 hours or more after 
birth) on cytokine production in response to each stimulant was investigated using logistic 
regression, with the log transformed value of the unstimulated (RPMI only) cytokine values 
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as a covariate. Results were expressed as geometric mean ratios (GMR) with 95% 
confidence intervals. One participant was an extreme outlier for all cytokines in 
unstimulated samples but this was successfully corrected for in stimulated cytokine results 
using the unstimulated value as a covariate; as this could not be done for the analysis of 
unstimulated cytokine results, this participant was excluded in this analysis. Data are 
presented graphically as GMR (95% CI) to illustrate the results across cytokine/stimulant 
pairs without emphasis on tests of statistical significance [17].  Subgroup effects (sex, mode 
of delivery and maternal BCG vaccination status) were investigated where there was 
statistical evidence of an interaction effect between BCG vaccination and the subgroup 
variable. In addition, to exclude the possibility of confounding by sex, mode of delivery, 
maternal BCG status or individual unstimulated cytokine values, the effect of BCG 
vaccination on cytokine expression, adjusted for these variables was investigated using 
multiple logistic regression. Sensitivity analyses were performed to investigate the effect of 
both excluding values assigned at the lower end of the standard curve and values 
extrapolated by the xMAP Luminex 200 Bioanalyser software.  
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Results 
 
Demographic features are outlined in Table 1. There was a high degree of standardisation in 
the processing of samples and laboratory procedures (Supplementary Table 1). Our data 
exhibited the marked inter-individual variability in cytokine responses in both stimulated 
and unstimulated samples characteristic of cytokine data (Supplementary data, Figure 1).  
 
In unstimulated (RPMI) samples, BCG-vaccinated infants showed increased production of IL-
6, IL-1ra and IL-1ß, however the evidence that this was a real effect was weak for IL-1ra and 
IL-1ß (Table 2).  For TLR agonist responses, chemokine and cytokine production was 
unchanged by BCG in response to Pam3Cysk4 and LPS, but was generally lower in BCG-
vaccinated infants in response to stimulation with the TLR ligands PEPG and R848. This 
effect was strongest for the cytokines IL-6, IL-10 and chemokines MIP-1α, MIP-1ß, MCP-1 
(Figure 2 and Supplementary data Table 2).  
 
In response to stimulation with heterologous bacteria, the chemokines and cytokines for 
which production was most consistently decreased were IL-1ra, MCP-1 and MIP-1ß, 
particularly in response to stimulation with L. monocytogenes, E. coli and S. pneumoniae, 
and the fungus C. albicans (Figure 2, Supplementary Table 2).  
 
Sex independently influenced cytokine responses in our population (data not shown). 
There was a significant interaction between sex and BCG vaccination for production of MIF, 
in response to stimulation with L. monocytogenes, H. influenzae, S. agalactiae, 
M. tuberculosis and R848 (Supplementary data Table 3). Separate analyses of males and 
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females showed there were generally lower MIF responses in BCG-vaccinated males and 
higher responses in BCG-vaccinated females. BCG-vaccinated females had higher MIF 
production in response to stimulation with S. agalactiae, whereas BCG-vaccinated males 
had lower MIF production in response to stimulation with the intra-cellular stimulants R848, 
L. monocytogenes, M. tuberculosis (Figure 3) compared to non BCG-vaccinated controls of 
the same sex.  
 
Mode of delivery independently influenced cytokine responses in our population (data not 
shown), however there was minimal evidence of an interaction between BCG-vaccination 
and mode of delivery on cytokine responses (Supplementary data Table 3). Despite 
randomisation of participants to BCG vaccination, attrition from the immunological study 
led to differences in the distribution of sex and mode of delivery between the two groups 
(Table 1). A multivariate regression model including these two variables and the log 
transformed unstimulated cytokine yielded the same results as the primary analysis and 
excluded confounding as a contributor to the primary results. 
  
Infants whose mothers had a history of BCG vaccination had increased production of IL-1ß, 
IL-1ra, IL6 and MIP-1α in response to Pam3Cysk4, IL6 and MIP-1α in response to H. 
influenzae, and of MIP-1ß in response to PEPG. Conversely, infants whose mothers were not 
BCG-vaccinated had higher production of TNF-α and IL-1ß in response to R848, and IL-10 
production in response to S. agalactiae independent of infant BCG vaccination status.  
 (Supplementary Table 2).  
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There was evidence of an interaction between maternal BCG vaccination status and infant 
BCG vaccination status for five cytokine/stimulant pairs (IFN-/S. pneumoniae, IL-1ß/BCG, 
MIP-1α/PEPG, MIP-1α/Pam3Cysk4, MIG/H. influenzae) (Supplementary Table 3). Separate 
analyses in infants of mothers who were BCG vaccinated and those whose mothers were 
not BCG-vaccinated showed that in the former, BCG-vaccinated infants had higher IFN- 
production in response to stimulation with S. pneumoniae, MIP-1α in response to PEPG and 
IL-10 production in response to Pam3Cysk4. Conversely for BCG-vaccinated infants whose 
mothers’ were not BCG vaccinated MIP-1α expression was increased in response to 
Pam3Cysk4 (Figure 4). 
 
Infants were categorised into those who were randomised early (less than 48 hours after 
birth) and late (48 hours or more after birth) (Supplementary Figure 2a and 2b). The interval 
between BCG vaccination and blood sampling was similar between both groups (median 
interval 7 days (range 0-11) vs 8 days (range 3-11)) (Supplementary Figure 2c).  
 
Compared to those in the late BCG vaccination group, infants in the early BCG vaccination 
group had significantly higher cytokine and chemokine production following stimulation 
with all stimulants except for BCG and M. tuberculosis (Supplementary Table 4).  
 
To determine how the timing of BCG vaccination influenced the results of the primary 
analysis, we compared cytokine production in the early BCG-vaccinated group with the non 
BCG-vaccinated group, and the late BCG-vaccinated group with the non BCG-vaccinated 
group (Supplementary Table 4). The influence of BCG vaccination on cytokine production 
was more marked in the late BCG-vaccinated group than in the early BCG-vaccinated group 
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when each was compared with the non BCG-vaccinated group. The relationship between 
the results of this subgroup analysis relevant to the cytokine/stimulant pairs identified as 
significant from our primary analysis is shown in Figure 5. 
 
Sensitivity analyses were performed for the primary outcome, i.e. the effect of BCG 
vaccination on cytokine responses following in vitro stimulation, to investigate the influence 
of (i) the assigned values at the lower end of the standard curve and (ii) the values 
extrapolated by Luminex Xmap software at both the upper and lower ends of the standard 
curve (Supplementary Table 5). Overall, the results of the primary analysis were preserved 
across sensitivity analyses. Notable differences were seen only for production of IL-1ra in 
response to R848, MIP-1ß in response to R848, and IFN- in response to several stimulants, 
including M. tuberculosis (Supplementary data Table 5).   
 
Discussion 
 
This study adds to the growing body of immunological evidence to explain the observed 
heterologous effects of BCG vaccination by finding differential cytokine production between 
BCG-vaccinated infants and non BCG-vaccinated infants both in unstimulated samples and 
following in vitro stimulation with TLR ligands and heterologous pathogens.  
 
The pattern of cytokine production observed in our study, using a well-validated system [18, 
19], was consistent with previous studies in neonates. IL-10 production was high relative to 
IFN- for all stimulants [19]. IL-6 production was relatively high compared to pro-
inflammatory cytokines such as TNF-α and IL-1ß [20]. In addition, there was robust 
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chemokine production in response to TLR ligand stimulation, particularly R848 [21]. These 
patterns were seen despite considerable inter-individual variability, both at in unstimulated 
samples and following stimulation [22]. 
 
In our study, compared to non BCG-vaccinated infants, BCG-vaccinated infants had reduced 
production of multiple cytokines and chemokines in response to stimulation with the TLR 
ligands PEPG (TLR 2/(Nod)-like receptor 1/2) and R848 (TLR 7/8). PEPG and R848 are potent 
activators of neonatal innate immunity when compared to Pam3CYSK43 (TLR2) and LPS 
(TLR4) [23] [24]. R848 induces neonatal antigen presenting cells leading to Th1 polarisation 
and production IL-12p70 and TNF-α in equivalent levels to adults [24]. Excess stimulation of 
TLR7/8 with R848 is associated with neutrophil-mediated lung injury following RSV infection 
and an increased incidence of viral-associated wheeze in mouse models [25, 26]. PEPG has 
endotoxic properties and potentiates LPS signalling, augmenting its pathogenicity in sepsis 
syndromes [27-29]. The observed differential production of MCP-1 following stimulation 
with several heterologous bacteria between BCG-vaccinated and non BCG-vaccinated 
infants is interesting in light of MCP-1’s pivotal role in the control of mycobacterial disease. 
Elevated levels of MCP-1 are associated with pro-inflammatory diseases, including asthma 
and multiple sclerosis, and cancer progression [30]. 
 
The modified neonatal cytokine profile induced by BCG vaccination in our study 
characterised by reduced anti-inflammatory cytokine (IL-10, IL-1ra) and IL-6 responses 
following stimulation with heterologous bacteria suggests a pro-inflammatory bias in the 
BCG-vaccinated infants in the context of bacterial challenge. A concomitant down-
regulation in production of several chemokines, including MCP-1, could reduce leukocyte 
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recruitment and associated tissue damage during infection. Overall, these effects might 
result in a less severe sepsis response that might contribute to the reduction in mortality 
reported in BCG-vaccinated infants in high mortality settings. 
 
Jensen et al also investigated the immunological non-specific effects of BCG by measuring 
cytokine responses in whole blood [15]. In low-birth weight infants in Guinea-Bissau, 
compared to non BCG-vaccinated infants, BCG-vaccinated infants had increased IL-1ß and 
TNF-α production in unstimulated samples. Consistent with this, we found increased IL-6 
and IL-1ra (but not TNF-α) in unstimulated samples. Also consistent, we found no effect of 
BCG vaccination on cytokine production following stimulation with LPS. In Jensen et al’s 
study, BCG-vaccinated infants had increased IL-1ß, IL-6 and TNF-α production in response to 
stimulation with Pam3Cysk4, whereas in our study BCG vaccination had not effect on 
cytokine responses to Pam3Cysk4. Several factors that influence cytokine production 
differed between our study and that of Jensen et al. These include ethnicity, geographic 
locations [31], age [32] (infants were sampled at a mean of 30 days of age in Guinea-Bissau 
in contrast to a mean of 7 days in our study), maternal HIV status [33], weight, gestational 
age, underlying health, hepatitis B vaccination status, maternal BCG vaccination status, 
blood sampling method and anticoagulant. Jensen et al’s conclusion that BCG vaccination 
results in a stronger pro-inflammatory profile is consistent with our findings, albeit through 
different mechanisms. 
 
Kleinnijenhuis et al also found a pro-inflammatory response to heterologous bacteria 
induced by BCG vaccination. In this study, in adults, increased IFN-, TNF- and IL-1 
production in PBMC was observed following stimulation with heat-killed M. tuberculosis, 
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S. aureus and C. albicans [16]. More recently, a similar study in infants born in the United 
Kingdom showed increased IL-6 production in PBMC stimulated with C. albicans, S. aureus 
and Pam3Cysk4 [34]. The authors’ attributed these changes to epigenetic reprogramming 
which resulted in ‘trained immunity’ or innate immune memory 
 
Our finding that maternal BCG vaccination influenced the production of cytokines in infants 
is interesting. Latent maternal TB infection is associated with increased production of pro-
inflammatory cytokines in response to mycobacterial stimulants in BCG-vaccinated infants 
[35]. Moreover, in a recently reported trial from Denmark, BCG-vaccinated infants had 
decreased infectious illnesses during the first three months of life if their mother had a 
history of BCG vaccination [36]. Two possible explanations might account for the 
potentiating effect of maternal BCG vaccination. Firstly, transplacentally-acquired maternal 
antibodies could modify the response to BCG in the infant. Secondly, trans-generational 
epigenetic changes in immune responses could be involved; such a phenomenon has been 
reported in lower organisms, but has not yet been studied in mammals[37, 38]. 
Understanding how maternal and infant mycobacterial exposures influence the neonatal 
response to BCG warrants further investigation. 
 
It is well recognised that vaccine responses are affected by sex [39]. Although BCG 
vaccination alone did not affect the production of MIF in our study, there was a significant 
interaction between BCG vaccination and sex for MIF production in response to several 
heterologous antigens. MIF is produced by macrophages, lymphocytes and pituitary cells 
both constitutively and in response to bacterial infection or stress [40]. MIF has been 
implicated in severe sepsis and malaria and the development of chronic inflammatory 
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diseases, including dementia and atherosclerosis [41, 42]. The high levels of MIF at baseline 
in the infants in our study are in line with previous findings [43]. Given its pivotal role in the 
control of sepsis, the sex-differential effect of BCG vaccination on MIF production observed 
in our study warrants further investigation. 
 
The effect of timing of administration of BCG on the vaccine response is complex. In our 
study, early BCG vaccination was associated with increased production of multiple cytokines 
across most stimulants when compared to late BCG vaccination. Furthermore, the effect of 
timing of BCG vaccination on the results of our primary analysis suggests these effects 
become more pronounced with older age. Interpretation of these results is difficult as the 
analysis is potentially confounded in our study by the older age of infants at blood sampling. 
 
The strengths of our study include our ability to randomise term infants because BCG is not 
routinely given in Australia. Another strength was the highly standardised and controlled 
protocols used for blood collection, handling of samples and laboratory assays [44]. 
Interpretation of the results of multiplex cytokine analysis need to take into consideration 
the effect of assigned values outside the limit of detection of the assay and values which 
have been extrapolated by the bioanalyser software. There is no agreed method for 
standardisation or reporting of these parameters and methods described in the literature 
are highly variable. The findings in our study were preserved across sensitivity analyses 
designed to examine the effect of these assigned variables. 
 
A potential limitation is that infants in our study were co-administered hepatitis B vaccine as 
part of the Australian immunisation schedule. BCG has been associated with effects on 
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hepatitis B antibody production in studies in the Gambia [45] and Australia [46], but not in 
South Africa [47]. The effects of hepatitis B vaccines on innate immunity are not well studied 
[48] and there have been no studies investigating the potential heterologous effects of 
hepatitis B vaccines or its interaction with BCG.  
 
A further limitation of our study is the inability to perform traditional sample size 
calculations. Marked variability in both baseline and stimulated levels of cytokines 
necessitate large sample sizes. This is particularly relevant in the interpretation of subset 
analyses. To avoid spurious results of statistical significance in the context of multiple 
comparisons in subgroups of data, we used interaction analyses to explore the effect of sex, 
mode of delivery and maternal BCG status on our primary outcome. To aid interpretation 
and avoid undue emphasis on tests of statistical significance or conversely discarding results 
that were not significant due to type 2 error, we presented all our analyses with confidence 
intervals [49].  
 
Based on our data, future studies on the innate immune response to BCG should focus on 
interrogation of chemokine-producing cells and pathways activated by R848 and PEPG, 
including TLR 7/8, TLR2, RIG and NOD. Furthermore, studies in high mortality settings would 
be required to confirm any association between patterns of innate immune modulation in 
vitro and clinical outcomes following infection.. 
 
In conclusion, our study provides evidence of differential cytokine responses to 
heterologous antigens between BCG vaccinated and non BCG-vaccinated term infants. The 
responses can be broadly described as inhibition of anti-inflammatory cytokine production, 
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as well as down-regulation of chemokine responses. Both sex and maternal BCG vaccination 
status interacted with BCG vaccination. This study supports the concept that BCG modifies 
the neonatal innate immune response. 
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Table & Figure legends 
 
Table 1: Baseline characteristics of study participants. 
 
Table 2: Geometric mean ratio (95% CI) for unstimulated cytokines (RPMI only). Univariate 
analysis was for the effect of BCG vaccination. 
 
Figure 1:  Flow sheet of eligible participants and relevant exclusions. Table shows number of 
individual stimulations done for each antigen. 
 
Figure 2: The effect of BCG vaccination on cytokine expression. Significant results p<0.05 are 
pale grey. GMR > 1.0 indicates cytokine levels were higher in BCG vaccinated subjects. PEPG 
- Peptidoglycan (TLR2), Pam3Cysk4 - (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-
(R)- Cys-(S)-Ser-(S)-Lys4OH, trihydrochloride, (TLR1/2) LPS - Lipopolysaccharide (TLR4), R848 
- remisiqumod (TLR7/8). 
 
Figure 3: Interaction and subgroup analysis for the effect of sex on BCG vaccination. MIF 
production (GMR 95%CI) for cytokine/stimulant pairs where a significant interaction 
between sex and BCG vaccination was seen are shown for the whole population, in girls 
alone and in boys alone. Pam3Cysk4 - (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-
(R)- Cys-(S)-Ser-(S)-Lys4OH, trihydrochloride, (TLR1/2), R848 - remisiqumod (TLR7/8). 
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Figure 4: Interaction and subgroup analysis for the effect of maternal BCG vaccination status 
on neonatal BCG vaccination. Cytokine responses (GMR 95%CI) for cytokine/stimulant pairs 
where a significant interaction between maternal BCG vaccination status and neonatal BCG 
vaccination was seen are shown for the whole population and then in each subgroup. 
Pam3Cysk4 - (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)- Cys-(S)-Ser-(S)-
Lys4OH, trihydrochloride, (TLR1/2), R848 - remisiqumod (TLR7/8 
 
Figure 5: Effect of the timing of BCG on the overall effect of BCG shown by the primary 
analysis. Cytokine responses (GMR 95%CI) for cytokine/stimulant pairs where a significant 
effect of BCG vaccination was seen are shown for the whole population and Peptidoglycan 
(TLR2). 
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 BCG-vaccinated 
n (%) 
Not BCG-vaccinated  
n (%) 
Total 
All   119 (56.1) 93 (43.9) 212 (100) 
Sex Male  58 (48.7) 43 (46.2) 101 (47.6) 
  Female  61 (51.3) 50 (53.8) 111 (52.3) 
Gestational age (weeks) Mean (SD) 39.3 (1.5) 39.2 (1.3) 39.3 (0.1)  
Birth weight (grams) Mean (SD) 3388 (487.3) 3333 (492.7) 3364 (489.3) 
Mode of delivery Vaginal delivery  93 (40.9) 62 (66.7) 126 (59.5) 
  Caesarean section 55 (46.3) 31 (33.3) 86 (40.5) 
Last trimester vaccination* Yes  59 (49.6) 43 (46.2) 102 (48.1) 
  No  58 (48.7) 49 (52.8) 107 (50.5)  
  Not reported 2 (1.7) 1 (1.1) 3 (1.4) 
Feeding Breast feeding 82(69.2) 67 (71.7) 149 (70.2) 
  Formula feeding 3 (2.4) 7 (7.6) 10 (4.8) 
  Combination  29 (24.2) 18 (19.6) 47 (22.2) 
  Not reported 5 (4.2) 1 (1.1) 6 (2.8) 
Table 1
Infant vitamin D supplementation Yes 64 (53.4) 48 (51.8) 112 (52.8) 
 No  55 (46.6) 45 (48.2)  100 (47.2) 
Day of BCG vaccination Mean (SD) 2.1 (1.9) - - 
 Median (IQR) 2 (0-6)   
Interval from randomisation to blood  (days)  Mean (SD) 6.9 (2.2) - - 
Timing of hepatitis B vaccination 
 
Hepatitis B alone 
Before BCG 
58 (48.7) 84 (90.3) 
- 
142 (67.1) 
 Same day as BCG 37 (31.2) - 37 (17.4) 
 After BCG 24 (20.1) - 24 (11.3) 
 Not reported 0 9 (9.7) 9 (4.2) 
Maternal BCG vaccinations status Yes 24 (20.2) 31 (33.3) 55 (25.9) 
 No  90 (75.6) 54 (58.1)  144 (67.9) 
 Not reported 5 (4.2) 8 (8.6) 13 (6.2) 
 
* Boostrix (DTPa) or influenza vaccine in the last trimester, in line with local recommendations 
 
Eligible for immunological 
study (n=447)
Excluded for clinical reasons 
(n=22)
Did not have a home visit
(n=118)
Eligible for whole blood assay 
(n=272)
Eligible for home visit  
(n=425)
Failed blood draw
(n=35)
Blood unsuitable for assay
(n=34)
Eligible for blood test
(n= 307)
Eligible for statistical analysis 
(n=212)
Eligible for cytokine analysis 
(n=238)
Technical error (n= 26)
BCG vaccinated
(n=119)
BCG unvaccinated
(n=93)
No of participants 
for each stimulant
Nil 212
BCG 129
Heat-killed pathogens
M. tuberculosis 98
S. agalactiae 113
S. aureus 98
S. pneumoniae 74
E. coli 157
H. influenzae 141
L. monocytogenes 69
C. albicans 86
TLR agonists
LPS 147
PEPG 147
Pam3CYSK4 128
R848 150
Figure 1 Click here to download Figure
FreyneB_HeterologouscytokineresponsespostBCG_Fig1.ppt
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine GMR (95% CI)  p-value 
IFN- 0.98 (0.8-1.2)  0.85 
TNF-α 1.0 (0.9-1.2)  0.80 
IL-1β 1.6 (0.8-3.0)  0.18 
IL-6 2.0 (1.1-3.7)  0.03 
MIF 1.0 (0.9-1.2)  0.90 
MIG 0.9 (0.8-1.1)  0.42 
MCP-1 1.2 (0.8-1.6)  0.41 
IL-8 1.0 (0.4-2.1))  0.94 
MIP-1α 0.8 (0.5-1.4)  0.5 
MIP-1β 1.0 (0.7-1.4)  1.00 
IL-1ra 1.9 (0.9-3.8)  0.08 
IL-10 1.0 (1.0-1.1  0.55 
Table 2
Figure 2 Click here to download Figure
FreyneB_HeterologouscytokineresponsespostBCG_Fig2.tiff
Figure 3 Click here to download Figure
FreyneB_HeterologouscytokineresponsespostBCG_Fig 3.tiff
Figure 4 Click here to download Figure
FreyneB_HeterologouscytokineresponsespostBCG_Fig4.tiff
Figure 5 Click here to download Figure FreyneB_HeterologousresponsespostBCG_Fig5.tiff 
The effect of neonatal BCG vaccination on cytokine responses to heterologous antigens in 
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 BCG- 
vaccinated 
Not BCG-
vaccinated 
Total 
All  n (%) 119 (56.1) 93 (43.9) 212 
Age at blood collection (days) Mean (SD) 9.1 (2.9) 8.6 (2.5) 8.9 (2.8) 
Volume of blood (mL) Mean (SD) 2.8 (1.6) 2.9 (1.6) 2.9 (1.6) 
Time between blood collection and 
stimulation (hours) 
Mean (SD) 4.0 (0.3) 4.1 (0.3) 4.0 (0.3) 
Within 4 hours ± 24 minutes n (%) 74 (62.2) 69 (74.2) 143 (67.5) 
Incubation duration (hours) Mean (SD) 20.5 (0.8) 20.3 (0.8) 20.4 (0.8) 
Within 20 ± 2 hours  n (%) 115 (96.6) 92 (99.2) 207 (97.6) 
 
Supplementary Table 1: Standardisation of blood collection, handling and laboratory methods. 
  
      BCG Maternal BCG 
Cytokine Stim Total 
(n) 
GMR 95%CI 
p  value 
GMR 95%CI 
p  value       LCI UCI   LCI UCI 
MIP-1β BCG 129 0.9 0.7 1.1 0.23 1.1 0.9 1.4 0.42 
  MTBK 98 1.1 0.8 1.4 0.55 1.2 0.9 1.6 0.28 
  LPS 147 0.8 0.5 1.1 0.14 0.9 0.6 1.4 0.73 
  PEPG 147 0.7 0.6 0.8 0.00 1.2 1.0 1.6 0.05 
  Pam3 128 1.0 0.8 1.3 0.96 1.2 0.9 1.6 0.16 
  R848 150 0.7 0.5 1.0 0.03 0.9 0.7 1.3 0.58 
  SA 98 0.8 0.7 1.1 0.14 1.2 0.9 1.5 0.25 
  SP 74 0.8 0.6 1.0 0.07 1.3 1.0 1.7 0.06 
  GBS 113 0.9 0.8 1.2 0.57 1.0 0.8 1.3 0.98 
  EC 157 0.8 0.6 1.0 0.05 1.1 0.8 1.4 0.66 
  HI 141 0.9 0.7 1.1 0.25 1.1 0.9 1.5 0.30 
  LM 69 0.7 0.5 1.0 0.03 1.0 0.7 1.4 0.95 
  CA 86 0.8 0.5 1.2 0.28 1.1 0.7 1.7 0.68 
MCP-1 BCG 129 1.0 0.8 1.3 0.98 1.0 0.8 1.4 0.77 
  MTBK 98 1.0 0.8 1.4 0.82 1.0 0.7 1.4 0.95 
  LPS 147 0.9 0.6 1.3 0.45 1.3 0.8 1.9 0.27 
  PEPG 147 0.8 0.6 1.0 0.04 1.2 0.9 1.6 0.14 
  Pam3 128 0.9 0.7 1.1 0.36 1.2 0.9 1.5 0.30 
  R848 150 0.8 0.7 1.0 0.01 1.1 0.9 1.4 0.29 
  SA 98 0.8 0.6 1.1 0.20 1.1 0.8 1.6 0.47 
  SP 74 0.7 0.5 0.9 0.01 1.2 0.8 1.6 0.37 
  GBS 113 0.9 0.7 1.1 0.28 1.0 0.7 1.3 0.91 
  EC 157 0.8 0.6 1.0 0.03 1.1 0.8 1.4 0.52 
  HI 141 0.8 0.7 1.0 0.07 1.1 0.8 1.3 0.63 
  LM 69 0.7 0.5 0.9 0.01 1.0 0.7 1.3 0.80 
  CA 86 0.6 0.4 0.9 0.01 1.3 0.8 1.9 0.28 
IL-8 BCG 129 1.0 0.9 1.3 0.70 1.1 0.9 1.4 0.38 
  MTBK 98 1.2 0.9 1.7 0.27 1.2 0.8 1.8 0.26 
  LPS 147 1.0 0.8 1.3 0.94 1.1 0.8 1.5 0.52 
  PEPG 147 0.9 0.7 1.1 0.37 1.1 0.9 1.4 0.40 
  Pam3 128 1.1 0.8 1.5 0.68 1.3 0.9 1.8 0.19 
  R848 150 0.9 0.7 1.2 0.70 0.9 0.7 1.2 0.58 
  SA 98 0.9 0.7 1.3 0.67 1.0 0.8 1.4 0.77 
  SP 74 0.8 0.7 1.1 0.17 1.0 0.8 1.3 0.87 
  GBS 113 1.0 0.8 1.3 0.95 1.0 0.7 1.2 0.79 
  EC 157 1.0 0.8 1.2 0.81 1.2 0.9 1.4 0.16 
  HI 141 1.0 0.8 1.2 0.92 1.1 0.9 1.4 0.30 
  LM 69 0.7 0.5 1.1 0.11 0.9 0.6 1.4 0.61 
  CA 86 0.8 0.5 1.1 0.15 1.2 0.8 1.9 0.37 
MIF BCG 129 0.9 0.8 1.0 0.06 1.0 0.9 1.1 0.79 
  MTBK 98 0.9 0.8 1.0 0.09 1.0 0.9 1.2 0.67 
  LPS 147 1.0 0.9 1.1 0.81 1.0 0.9 1.1 0.44 
  PEPG 147 1.0 0.9 1.1 0.42 1.0 0.9 1.1 0.98 
  Pam3 128 0.9 0.8 1.1 0.29 1.0 0.8 1.1 0.62 
  R848 150 1.0 0.9 1.0 0.28 1.0 0.9 1.1 0.81 
  SA 98 1.0 0.9 1.1 0.76 1.0 0.9 1.1 0.62 
  SP 74 1.0 0.9 1.1 0.72 1.0 0.9 1.2 0.69 
  GBS 113 1.1 0.9 1.2 0.32 1.0 0.9 1.1 0.97 
 
EC 157 1.1 1.0 1.1 0.25 1.0 0.9 1.1 0.64 
 HI 141 1.0 0.9 1.1 0.56 1.0 0.9 1.1 0.44 
  LM 69 0.9 0.8 1.0 0.07 1.0 0.9 1.2 0.61 
  CA 86 1.0 0.9 1.1 0.88 1.0 0.9 1.1 0.76 
Supplementary data Table 2 p1. 
Supplementary data Table 2 p2. 
 
 
 
   BCG Maternal BCG 
Cytokine Stim Total 
(n) 
GMR 95%CI p  value GMR 95%CI p  value 
   LCI UCI  LCI UCI 
IL-1ra BCG 129 1.1 0.7 1.7 0.62 1.0 0.7 1.6 0.95 
 MTBK 98 1.0 0.7 1.6 0.85 1.3 0.8 2.0 0.34 
 LPS 147 0.8 0.6 1.3 0.40 1.3 0.8 2.0 0.32 
 PEPG 147 0.9 0.7 1.2 0.46 1.0 0.7 1.3 0.98 
 Pam3 128 0.8 0.6 1.2 0.32 1.5 1.0 2.2 0.03 
 R848 150 0.8 0.6 1.0 0.06 1.3 1.0 1.7 0.08 
 SA 98 0.8 0.5 1.2 0.19 1.5 0.9 2.4 0.09 
 SP 74 0.7 0.5 1.1 0.09 1.3 0.8 2.1 0.26 
 GBS 113 0.9 0.6 1.2 0.37 1.1 0.8 1.7 0.49 
 EC 157 0.8 0.6 1.1 0.13 1.1 0.8 1.4 0.59 
 HI 141 0.8 0.6 1.1 0.25 1.2 0.9 1.7 0.23 
 LM 69 0.5 0.3 0.9 0.01 1.5 0.8 2.8 0.18 
 CA 86 0.7 0.4 1.1 0.10 1.3 0.7 2.2 0.43 
IL-10 BCG 129 1.0 0.7 1.3 0.77 1.0 0.7 1.4 0.81 
 MTBK 98 1.3 0.7 2.5 0.44 0.9 0.5 1.8 0.84 
 LPS 147 1.1 0.7 1.9 0.62 0.6 0.3 1.0 0.06 
 PEPG 147 0.8 0.7 1.0 0.09 0.9 0.7 1.1 0.30 
 Pam3 128 0.8 0.5 1.4 0.49 1.1 0.6 1.8 0.81 
 R848 150 0.7 0.6 1.0 0.02 0.8 0.6 1.0 0.08 
 SA 98 0.9 0.6 1.3 0.61 1.0 0.6 1.5 0.88 
 SP 74 1.1 0.8 1.5 0.62 0.9 0.6 1.2 0.38 
 GBS 113 1.2 0.9 1.6 0.18 0.7 0.6 1.0 0.05 
 EC 157 0.9 0.7 1.1 0.23 0.9 0.7 1.1 0.22 
 HI 141 0.9 0.7 1.1 0.31 0.9 0.7 1.1 0.22 
 LM 69 0.9 0.6 1.3 0.47 0.8 0.5 1.3 0.45 
 CA 86 1.2 0.5 2.9 0.64 1.0 0.4 2.7 0.93 
MIG BCG 129 0.9 0.8 1.0 0.14 1.1 1.0 1.4 0.11 
 MTBK 98 0.8 0.7 1.0 0.06 1.0 0.8 1.3 0.80 
 LPS 147 1.1 0.9 1.3 0.50 0.9 0.8 1.2 0.60 
 PEPG 147 0.9 0.7 1.1 0.17 1.1 0.9 1.4 0.49 
 Pam3 128 1.0 0.9 1.1 0.81 0.9 0.8 1.1 0.23 
 R848 150 0.9 0.7 1.3 0.70 1.1 0.8 1.5 0.65 
 SA 98 1.0 0.8 1.2 0.99 1.0 0.8 1.2 0.85 
 SP 74 1.1 0.8 1.4 0.71 1.1 0.8 1.5 0.64 
 GBS 113 1.1 0.8 1.4 0.63 1.0 0.8 1.3 0.90 
 EC 157 1.0 0.9 1.1 0.94 1.0 0.9 1.2 0.67 
 HI 141 0.9 0.8 1.1 0.45 1.1 0.9 1.2 0.48 
 LM 69 0.9 0.7 1.1 0.19 1.1 0.8 1.4 0.63 
 CA 86 0.9 0.8 1.1 0.34 1.0 0.9 1.2 0.92 
MIP-1α BCG 129 0.9 0.7 1.1 0.28 1.1 0.8 1.4 0.69 
 MTBK 98 1.1 0.6 1.9 0.76 1.2 0.6 2.2 0.60 
 LPS 147 0.9 0.6 1.4 0.75 1.0 0.6 1.6 0.99 
 PEPG 147 0.7 0.5 0.9 0.01 1.3 1.0 1.8 0.06 
 Pam3 128 1.2 0.7 2.1 0.57 2.3 1.3 4.3 0.01 
 R848 150 0.7 0.5 1.0 0.06 0.9 0.6 1.3 0.64 
 SA 98 0.7 0.4 1.1 0.15 1.7 1.0 2.8 0.07 
 SP 74 0.8 0.6 1.2 0.27 1.3 0.9 1.8 0.17 
 GBS 113 1.1 0.7 1.6 0.73 1.4 0.9 2.0 0.15 
 EC 157 0.9 0.7 1.2 0.50 1.2 0.9 1.5 0.24 
 HI 141 0.9 0.6 1.1 0.25 1.4 1.0 1.8 0.04 
 LM 69 0.8 0.4 1.4 0.38 1.1 0.5 2.1 0.89 
 CA 86 0.7 0.3 1.5 0.38 1.2 0.5 2.8 0.60 
      BCG Maternal BCG 
Cytokine Stim Total 
(n) 
GMR 95%CI 
p  value 
GMR 95%CI 
p  value       LCI UCI   LCI UCI 
IL-1β BCG 129 0.9 0.8 1.1 0.38 1.0 0.8 1.2 0.89 
  MTBK 98 1.1 0.6 1.8 0.76 1.1 0.6 2.0 0.75 
  LPS 147 0.9 0.6 1.3 0.46 0.7 0.5 1.1 0.11 
  PEPG 147 0.9 0.7 1.1 0.27 1.1 0.8 1.4 0.58 
  Pam3 128 1.0 0.7 1.4 0.91 1.5 1.0 2.2 0.04 
  R848 150 0.8 0.6 1.2 0.30 0.6 0.4 1.0 0.03 
  SA 98 0.8 0.5 1.1 0.16 1.4 0.9 2.0 0.12 
  SP 74 1.0 0.7 1.4 0.98 1.1 0.8 1.5 0.68 
  GBS 113 1.0 0.7 1.3 0.75 1.1 0.8 1.5 0.58 
  EC 157 1.1 0.8 1.4 0.68 1.2 0.9 1.6 0.27 
  HI 141 0.9 0.7 1.2 0.63 1.2 0.9 1.7 0.13 
  LM 69 0.9 0.6 1.2 0.40 0.9 0.6 1.3 0.43 
  CA 86 0.8 0.4 1.5 0.48 1.2 0.6 2.4 0.60 
IL-6 BCG 129 1.0 0.8 1.2 0.77 1.0 0.8 1.3 0.87 
  MTBK 98 1.1 0.6 1.8 0.74 1.1 0.6 2.0 0.70 
  LPS 147 0.9 0.7 1.3 0.66 1.0 0.7 1.4 0.96 
  PEPG 147 0.8 0.6 1.0 0.02 1.2 0.9 1.5 0.17 
  Pam3 128 0.9 0.5 1.6 0.80 2.2 1.2 3.9 0.01 
  R848 150 0.7 0.6 0.9 0.01 0.9 0.7 1.1 0.26 
  SA 98 0.7 0.4 1.1 0.09 1.5 0.9 2.4 0.13 
  SP 74 0.9 0.7 1.3 0.73 1.2 0.8 1.8 0.35 
  GBS 113 0.9 0.7 1.3 0.69 1.2 0.8 1.6 0.39 
  EC 157 0.9 0.7 1.1 0.22 1.2 1.0 1.5 0.10 
  HI 141 0.8 0.6 1.1 0.14 1.3 1.0 1.8 0.03 
  LM 69 0.7 0.4 1.2 0.17 1.2 0.6 2.3 0.59 
  CA 86 0.6 0.3 1.5 0.26 1.8 0.7 4.7 0.25 
TNF-α BCG 129 0.9 0.7 1.1 0.35 1.0 0.8 1.3 0.83 
  MTBK 98 0.9 0.6 1.4 0.67 1.4 0.9 2.3 0.18 
  LPS 147 1.2 0.9 1.6 0.14 0.8 0.6 1.1 0.19 
  PEPG 147 1.0 0.8 1.2 0.89 1.2 1.0 1.5 0.10 
  Pam3 128 1.0 0.8 1.4 0.74 0.9 0.7 1.2 0.43 
  R848 150 0.8 0.5 1.3 0.42 0.5 0.3 0.9 0.01 
  SA 98 0.9 0.6 1.3 0.49 1.2 0.8 1.7 0.47 
  SP 74 1.0 0.7 1.3 0.94 1.1 0.8 1.5 0.68 
  GBS 113 1.1 0.9 1.5 0.34 1.0 0.8 1.4 0.78 
  EC 157 1.0 0.9 1.2 0.71 1.0 0.8 1.2 0.71 
  HI 141 1.0 0.8 1.2 0.83 1.1 0.9 1.4 0.33 
  LM 69 0.9 0.6 1.2 0.41 1.0 0.7 1.4 0.98 
  CA 86 0.8 0.5 1.4 0.52 0.9 0.5 1.6 0.69 
IFN-γ BCG 129 1.9 0.9 4.0 0.10 1.3 0.6 3.1 0.49 
  MTBK 98 1.5 0.8 2.7 0.16 1.3 0.6 2.5 0.49 
  LPS 147 1.2 0.6 2.6 0.56 0.7 0.3 1.6 0.37 
  PEPG 147 0.7 0.3 1.4 0.33 0.9 0.4 2.0 0.84 
  Pam3 128 1.2 0.7 2.0 0.51 1.0 0.6 1.8 0.96 
  R848 150 0.8 0.3 1.8 0.52 0.7 0.3 1.7 0.41 
  SA 98 0.8 0.3 1.9 0.56 1.5 0.5 3.9 0.45 
  SP 74 1.0 0.4 2.5 0.95 0.6 0.2 1.7 0.38 
  GBS 113 1.3 0.6 3.2 0.50 1.8 0.7 4.5 0.21 
  EC 157 1.2 0.7 2.3 0.51 0.9 0.5 1.8 0.80 
  HI 141 1.6 0.8 3.1 0.19 0.9 0.4 1.8 0.69 
  LM 69 1.4 0.5 3.7 0.47 0.6 0.2 1.7 0.33 
  CA 86 0.8 0.4 1.6 0.47 0.7 0.3 1.5 0.34 
Supplementary data Table 2 p3. 
 
Supplementary Table 3 
  
 Age at BCG vaccination
0 1 2 3 4 5 6 7 9
0
50
100
150
Early BCG
Late BCG
a)
Day of life BCG vaccination given
%
 p
a
rt
ic
ip
a
n
ts
 / 
g
ro
u
p
Number of days between BCG and blood draw
3 4 5 6 7 8 9 10 11
0
20
40
60
80
Early BCG
Late BCG
b)
Days between BCG and blood sample
%
 p
a
rt
ic
ip
a
n
ts
Age at blood sampling
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20
0
20
40
60
80
Early BCG
Late BCG
Controls
b)
Day of life blood sample taken
%
 p
a
rt
ic
ip
a
n
ts
Fig 5: Relationship between timing of randomisation (early BCG = randomisation < 48 hours, 
late BCG= randomisation >48 hours) and a)age at BCG vaccination, b) age at blood sample  
and c) time to blood sample .
 
Supplementary Figure 2
Cytokine Stimulant Total	(n) Early	(n) Late	(n) Controls	(n) GMR p	value GMR p	value GMR p	value GMR p	value Cytokine Stimulant Total	(n) Early	(n) Late	(n Controls	(n) GMR p	value GMR p	value GMR p	value GMR p	value
LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI
IL-1ra BCG 129 51 19 59 1.1 0.7 1.7 0.62 0.7 0.4 1.2 0.18 1.3 0.8 1.9 0.30 0.9 0.4 1.7 0.64 IL-8 BCG 129 51 19 59 1.0 0.9 1.3 0.70 0.9 0.7 1.2 0.44 1.1 0.9 1.3 0.53 1.0 0.7 1.3 0.73
MTBK 98 37 17 44 1.0 0.7 1.6 0.85 0.7 0.4 1.3 0.26 1.3 0.8 2.0 0.28 0.8 0.4 1.7 0.57 MTBK 98 37 17 44 1.2 0.9 1.7 0.27 1.1 0.7 1.8 0.63 1.2 0.8 1.8 0.45 1.3 0.8 2.1 0.25
LPS 147 54 26 67 0.8 0.6 1.3 0.40 0.6 0.4 1.0 0.07 1.0 0.7 1.6 0.94 0.6 0.3 1.1 0.09 LPS 147 54 26 67 1.0 0.8 1.3 0.94 0.7 0.5 1.0 0.05 1.1 0.8 1.6 0.44 0.8 0.5 1.2 0.27
PEPG 147 53 26 67 0.9 0.7 1.2 0.46 0.8 0.6 1.0 0.08 1.0 0.8 1.4 0.90 0.7 0.5 1.1 0.15 PEPG 147 53 26 67 0.9 0.7 1.1 0.37 0.8 0.6 1.1 0.11 1.0 0.8 1.3 0.90 0.8 0.6 1.0 0.06
Pam3 128 49 21 58 0.8 0.6 1.2 0.32 1.0 0.7 1.7 0.86 0.9 0.6 1.2 0.43 0.8 0.5 1.4 0.44 Pam3 128 49 21 58 1.1 0.8 1.5 0.68 0.9 0.6 1.4 0.63 1.1 0.8 1.6 0.61 1.0 0.7 1.6 0.88
R848 150 57 27 66 0.8 0.6 1.0 0.06 0.8 0.6 1.2 0.28 0.8 0.6 1.1 0.22 0.7 0.5 1.0 0.04 R848 150 57 27 66 0.9 0.7 1.2 0.70 0.7 0.4 1.0 0.05 1.1 0.8 1.5 0.62 0.7 0.5 1.0 0.08
SA 98 36 16 46 0.8 0.5 1.2 0.19 0.8 0.4 1.5 0.49 0.8 0.5 1.3 0.45 0.6 0.3 1.2 0.14 SA 98 36 16 46 0.9 0.7 1.3 0.67 1.1 0.8 1.7 0.52 0.9 0.7 1.3 0.56 1.0 0.7 1.6 0.94
SP 74 27 13 34 0.7 0.5 1.1 0.09 0.6 0.3 1.0 0.06 0.9 0.6 1.4 0.66 0.5 0.2 0.9 0.03 SP 74 27 13 34 0.8 0.7 1.1 0.17 1.0 0.7 1.4 0.93 0.8 0.6 1.1 0.17 0.9 0.6 1.2 0.39
GBS 113 43 19 51 0.9 0.6 1.2 0.37 0.8 0.5 1.3 0.30 1.0 0.7 1.4 0.78 0.7 0.4 1.2 0.17 GBS 113 43 19 51 1.0 0.8 1.3 0.95 0.7 0.5 1.0 0.05 1.1 0.9 1.4 0.39 0.8 0.6 1.1 0.14
EC 157 62 28 67 0.8 0.6 1.1 0.13 0.7 0.5 1.0 0.05 0.9 0.7 1.2 0.67 0.6 0.4 0.9 0.02 EC 157 62 28 67 1.0 0.8 1.2 0.81 0.9 0.7 1.1 0.26 1.1 0.9 1.3 0.58 0.9 0.7 1.2 0.61
HI 141 56 22 63 0.8 0.6 1.1 0.25 0.8 0.5 1.2 0.23 0.9 0.7 1.3 0.69 0.7 0.4 1.1 0.11 HI 141 56 22 63 1.0 0.8 1.2 0.92 0.9 0.7 1.2 0.41 1.0 0.8 1.3 0.70 0.9 0.7 1.2 0.65
LM 69 23 12 33 0.5 0.3 0.9 0.01 0.9 0.4 2.0 0.79 0.6 0.3 1.1 0.09 0.4 0.2 0.9 0.03 LM 69 23 12 33 0.7 0.5 1.1 0.11 1.0 0.6 1.7 0.92 0.7 0.5 1.2 0.19 0.8 0.5 1.2 0.27
CA 86 32 15 39 0.7 0.4 1.1 0.10 1.0 0.5 2.1 0.97 0.7 0.4 1.2 0.19 0.6 0.3 1.3 0.20 CA 86 32 15 39 0.8 0.5 1.1 0.15 1.2 0.7 2.0 0.55 0.7 0.5 1.1 0.13 0.8 0.5 1.4 0.50
IL-10 BCG 129 51 19 59 1.0 0.7 1.3 0.77 0.7 0.5 1.1 0.15 1.0 0.7 1.5 0.86 0.8 0.4 1.3 0.35 MIF BCG 129 51 19 59 0.9 0.8 1.0 0.06 0.9 0.8 1.1 0.34 0.9 0.8 1.0 0.18 0.9 0.7 1.0 0.04
MTBK 98 37 17 44 1.3 0.7 2.5 0.44 1.3 0.6 3.0 0.52 1.2 0.5 2.6 0.66 1.6 0.6 3.9 0.34 MTBK 98 37 17 44 0.9 0.8 1.0 0.09 0.9 0.8 1.1 0.32 0.9 0.8 1.1 0.26 0.9 0.7 1.0 0.06
LPS 147 54 26 67 1.1 0.7 1.9 0.62 0.6 0.3 1.1 0.08 1.4 0.8 2.4 0.27 0.8 0.4 1.6 0.49 LPS 147 54 26 67 1.0 0.9 1.1 0.81 1.0 0.9 1.2 0.74 1.0 0.9 1.1 0.71 1.0 0.9 1.1 0.93
PEPG 147 53 26 67 0.8 0.7 1.0 0.09 0.7 0.5 0.9 0.00 1.0 0.8 1.2 0.68 0.7 0.5 0.9 0.00 PEPG 147 53 26 67 1.0 0.9 1.1 0.42 1.0 0.8 1.1 0.46 1.0 0.9 1.1 0.68 0.9 0.8 1.1 0.27
Pam3 128 49 21 58 0.8 0.5 1.4 0.49 1.3 0.6 2.8 0.52 0.8 0.5 1.4 0.41 1.0 0.5 1.9 0.98 Pam3 128 49 21 58 0.9 0.8 1.1 0.29 1.0 0.8 1.3 0.85 0.9 0.8 1.1 0.33 0.9 0.8 1.1 0.30
R848 150 57 27 66 0.7 0.6 1.0 0.02 0.8 0.6 1.2 0.38 0.8 0.6 1.0 0.08 0.7 0.5 0.9 0.02 R848 150 57 27 66 1.0 0.9 1.0 0.28 1.0 0.9 1.1 0.78 1.0 0.9 1.1 0.42 0.9 0.8 1.0 0.26
SA 98 36 16 46 0.9 0.6 1.3 0.61 0.7 0.4 1.2 0.18 1.0 0.7 1.5 0.98 0.7 0.4 1.3 0.29 SA 98 36 16 46 1.0 0.9 1.1 0.76 1.0 0.9 1.1 0.92 1.0 0.9 1.1 0.82 1.0 0.8 1.1 0.78
SP 74 27 13 34 1.1 0.8 1.5 0.62 0.5 0.3 0.7 0.00 1.3 1.0 1.9 0.07 0.7 0.4 1.1 0.10 SP 74 27 13 34 1.0 0.9 1.1 0.72 1.0 0.8 1.2 0.71 1.0 0.8 1.2 0.87 1.0 0.8 1.2 0.60
GBS 113 43 19 51 1.2 0.9 1.6 0.18 0.8 0.5 1.1 0.17 1.3 1.0 1.8 0.08 1.0 0.7 1.5 0.95 GBS 113 43 19 51 1.1 0.9 1.2 0.32 1.0 0.8 1.1 0.70 1.1 0.9 1.2 0.32 1.0 0.9 1.2 0.66
EC 157 62 28 67 0.9 0.7 1.1 0.23 0.7 0.5 0.9 0.00 1.0 0.8 1.2 0.99 0.7 0.6 0.9 0.00 EC 157 62 28 67 1.1 1.0 1.1 0.25 1.0 0.9 1.2 0.75 1.0 0.9 1.2 0.37 1.1 0.9 1.2 0.29
HI 141 56 22 63 0.9 0.7 1.1 0.31 0.7 0.5 1.0 0.03 1.0 0.8 1.2 0.93 0.7 0.5 0.9 0.02 HI 141 56 22 63 1.0 0.9 1.1 0.56 1.1 0.9 1.2 0.40 1.0 0.9 1.1 0.37 1.0 0.9 1.1 0.77
LM 69 23 12 33 0.9 0.6 1.3 0.47 0.8 0.5 1.5 0.58 0.9 0.5 1.5 0.67 0.8 0.4 1.5 0.44 LM 69 23 12 33 0.9 0.8 1.0 0.07 1.1 0.9 1.3 0.22 0.9 0.7 1.0 0.04 1.0 0.8 1.1 0.57
CA 86 32 15 39 1.2 0.5 2.9 0.64 0.7 0.2 2.4 0.58 1.4 0.5 3.6 0.52 1.0 0.3 3.1 0.96 CA 86 32 15 39 1.0 0.9 1.1 0.88 1.0 0.8 1.2 0.81 1.0 0.9 1.1 0.98 1.0 0.8 1.1 0.72
MIG BCG 129 51 19 59 0.9 0.8 1.0 0.14 1.0 0.8 1.2 0.98 0.9 0.8 1.0 0.16 0.9 0.7 1.1 0.35 IL-1β BCG 129 51 19 59 0.9 0.8 1.1 0.38 0.9 0.6 1.2 0.47 0.9 0.8 1.2 0.61 0.8 0.6 1.1 0.17
MTBK 98 37 17 44 0.8 0.7 1.0 0.06 1.0 0.7 1.4 0.94 0.8 0.6 1.1 0.12 0.8 0.6 1.0 0.10 MTBK 98 37 17 44 1.1 0.6 1.8 0.76 1.1 0.5 2.3 0.88 1.1 0.6 2.1 0.69 1.0 0.5 2.2 0.89
LPS 147 54 26 67 1.1 0.9 1.3 0.50 0.8 0.6 1.1 0.20 1.1 0.9 1.4 0.25 0.9 0.8 1.1 0.53 LPS 147 54 26 67 0.9 0.6 1.3 0.46 0.5 0.3 0.9 0.02 1.1 0.7 1.6 0.72 0.6 0.3 1.0 0.05
PEPG 147 53 26 67 0.9 0.7 1.1 0.17 1.1 0.8 1.4 0.51 0.8 0.7 1.1 0.14 0.9 0.7 1.2 0.54 PEPG 147 53 26 67 0.9 0.7 1.1 0.27 0.7 0.5 0.9 0.01 1.0 0.7 1.3 0.95 0.7 0.5 1.0 0.03
Pam3 128 49 21 58 1.0 0.9 1.1 0.81 1.1 0.9 1.4 0.34 1.0 0.8 1.1 0.52 1.1 0.9 1.2 0.30 Pam3 128 49 21 58 1.0 0.7 1.4 0.91 0.5 0.3 0.9 0.02 1.2 0.8 1.8 0.41 0.6 0.4 1.1 0.08
R848 150 57 27 66 0.9 0.7 1.3 0.70 0.9 0.6 1.5 0.74 1.0 0.7 1.4 0.85 0.9 0.6 1.3 0.41 R848 150 57 27 66 0.8 0.6 1.2 0.30 0.7 0.4 1.1 0.13 1.0 0.6 1.4 0.81 0.6 0.4 1.0 0.06
SA 98 36 16 46 1.0 0.8 1.2 0.99 1.1 0.8 1.6 0.41 1.0 0.8 1.2 0.71 1.1 0.8 1.5 0.47 SA 98 36 16 46 0.8 0.5 1.1 0.16 0.8 0.5 1.4 0.39 0.8 0.6 1.2 0.31 0.7 0.4 1.1 0.14
SP 74 27 13 34 1.1 0.8 1.4 0.71 0.7 0.5 1.1 0.15 1.2 0.9 1.6 0.31 0.8 0.6 1.3 0.41 SP 74 27 13 34 1.0 0.7 1.4 0.98 0.7 0.4 1.0 0.05 1.2 0.8 1.7 0.41 0.8 0.5 1.2 0.24
GBS 113 43 19 51 1.1 0.8 1.4 0.63 0.9 0.6 1.3 0.65 1.1 0.8 1.4 0.55 1.0 0.7 1.4 0.98 GBS 113 43 19 51 1.0 0.7 1.3 0.75 0.6 0.5 0.9 0.01 1.1 0.8 1.5 0.58 0.7 0.5 1.1 0.12
EC 157 62 28 67 1.0 0.9 1.1 0.94 0.9 0.8 1.1 0.50 1.0 0.9 1.2 0.73 0.9 0.8 1.1 0.50 EC 157 62 28 67 1.1 0.8 1.4 0.68 0.7 0.5 1.0 0.03 1.2 0.9 1.6 0.23 0.8 0.6 1.2 0.29
HI 141 56 22 63 0.9 0.8 1.1 0.45 1.0 0.8 1.2 0.86 1.0 0.8 1.1 0.55 0.9 0.8 1.1 0.43 HI 141 56 22 63 0.9 0.7 1.2 0.63 0.6 0.4 0.9 0.01 1.1 0.8 1.5 0.53 0.6 0.4 0.9 0.03
LM 69 23 12 33 0.9 0.7 1.1 0.19 0.9 0.7 1.3 0.73 0.9 0.7 1.1 0.32 0.8 0.6 1.2 0.32 LM 69 23 12 33 0.9 0.6 1.2 0.40 0.8 0.5 1.4 0.46 0.9 0.6 1.4 0.72 0.8 0.4 1.3 0.28
CA 86 32 15 39 0.9 0.8 1.1 0.34 1.1 0.9 1.4 0.19 0.9 0.8 1.1 0.19 1.0 0.8 1.2 0.90 CA 86 32 15 39 0.8 0.4 1.5 0.48 0.7 0.3 2.0 0.55 0.9 0.4 1.8 0.72 0.7 0.3 1.4 0.27
MIP-1α BCG 129 51 19 59 0.9 0.7 1.1 0.28 0.9 0.6 1.3 0.45 0.9 0.7 1.2 0.56 0.8 0.6 1.0 0.09 IL-6 BCG 129 51 19 59 1.0 0.8 1.2 0.77 0.8 0.6 1.1 0.24 1.0 0.8 1.3 0.88 0.8 0.6 1.1 0.25
MTBK 98 37 17 44 1.1 0.6 1.9 0.76 1.0 0.5 2.2 0.93 1.1 0.6 2.0 0.77 1.1 0.5 2.3 0.81 MTBK 98 37 17 44 1.1 0.6 1.8 0.74 1.4 0.7 3.1 0.35 1.0 0.5 1.9 0.99 1.3 0.6 2.5 0.49
LPS 147 54 26 67 0.9 0.6 1.4 0.75 0.5 0.3 0.9 0.02 1.2 0.7 1.9 0.55 0.6 0.3 1.2 0.13 LPS 147 54 26 67 0.9 0.7 1.3 0.66 0.6 0.4 0.9 0.00 1.1 0.8 1.5 0.56 0.7 0.4 1.0 0.07
PEPG 147 53 26 67 0.7 0.5 0.9 0.01 0.7 0.5 1.0 0.03 0.8 0.6 1.1 0.14 0.6 0.4 0.8 0.00 PEPG 147 53 26 67 0.8 0.6 1.0 0.02 0.7 0.5 0.9 0.01 0.9 0.7 1.1 0.25 0.6 0.5 0.8 0.00
Pam3 128 49 21 58 1.2 0.7 2.1 0.57 1.1 0.5 2.2 0.86 1.2 0.6 2.2 0.62 1.3 0.5 3.0 0.59 Pam3 128 49 21 58 0.9 0.5 1.6 0.80 0.9 0.4 1.9 0.73 1.0 0.5 1.8 0.91 0.9 0.4 2.0 0.75
R848 150 57 27 66 0.7 0.5 1.0 0.06 0.6 0.4 1.0 0.04 0.9 0.6 1.2 0.41 0.5 0.4 0.8 0.00 R848 150 57 27 66 0.7 0.6 0.9 0.01 0.7 0.5 1.1 0.09 0.8 0.6 1.0 0.07 0.6 0.4 0.8 0.00
SA 98 36 16 46 0.7 0.4 1.1 0.15 0.9 0.4 1.7 0.63 0.7 0.4 1.2 0.25 0.6 0.3 1.4 0.24 SA 98 36 16 46 0.7 0.4 1.1 0.09 0.9 0.5 1.7 0.69 0.7 0.4 1.1 0.14 0.6 0.3 1.3 0.19
SP 74 27 13 34 0.8 0.6 1.2 0.27 0.8 0.5 1.2 0.26 0.9 0.6 1.3 0.58 0.7 0.4 1.2 0.17 SP 74 27 13 34 0.9 0.7 1.3 0.73 0.7 0.5 1.2 0.17 1.0 0.7 1.5 0.85 0.8 0.4 1.4 0.39
GBS 113 43 19 51 1.1 0.7 1.6 0.73 0.7 0.4 1.2 0.19 1.2 0.8 1.8 0.43 0.9 0.5 1.5 0.60 GBS 113 43 19 51 0.9 0.7 1.3 0.69 0.7 0.5 1.1 0.12 1.0 0.7 1.5 0.84 0.7 0.5 1.2 0.22
EC 157 62 28 67 0.9 0.7 1.2 0.50 0.7 0.5 1.0 0.07 1.0 0.8 1.3 0.94 0.8 0.5 1.1 0.12 EC 157 62 28 67 0.9 0.7 1.1 0.22 0.7 0.6 1.0 0.05 0.9 0.7 1.2 0.67 0.7 0.5 1.0 0.04
HI 141 56 22 63 0.9 0.6 1.1 0.25 0.7 0.5 1.1 0.11 0.9 0.7 1.3 0.65 0.7 0.5 1.0 0.07 HI 141 56 22 63 0.8 0.6 1.1 0.14 0.8 0.5 1.1 0.11 0.9 0.7 1.2 0.44 0.7 0.5 1.0 0.05
LM 69 23 12 33 0.8 0.4 1.4 0.38 1.2 0.5 3.2 0.65 0.7 0.3 1.4 0.32 0.9 0.4 2.1 0.75 LM 69 23 12 33 0.7 0.4 1.2 0.17 0.8 0.4 1.9 0.66 0.7 0.4 1.4 0.32 0.6 0.3 1.4 0.23
CA 86 32 15 39 0.7 0.3 1.5 0.38 0.9 0.3 2.6 0.83 0.7 0.3 1.7 0.50 0.7 0.3 1.7 0.40 CA 86 32 15 39 0.6 0.3 1.5 0.26 0.6 0.1 2.9 0.56 0.7 0.3 1.8 0.43 0.5 0.2 1.5 0.21
MIP-1β BCG 129 51 19 59 0.9 0.7 1.1 0.23 0.8 0.6 1.0 0.06 1.0 0.8 1.2 0.69 0.7 0.5 1.0 0.03 TNF-α BCG 129 51 19 59 0.9 0.7 1.1 0.35 0.8 0.5 1.1 0.15 1.0 0.8 1.2 0.73 0.7 0.5 1.0 0.07
MTBK 98 37 17 44 1.1 0.8 1.4 0.55 0.9 0.6 1.3 0.55 1.1 0.8 1.6 0.43 1.0 0.7 1.5 1.00 MTBK 98 37 17 44 0.9 0.6 1.4 0.67 1.0 0.5 2.0 0.91 0.9 0.5 1.5 0.68 0.9 0.5 1.7 0.78
LPS 147 54 26 67 0.8 0.5 1.1 0.14 0.6 0.4 0.8 0.01 0.9 0.6 1.4 0.71 0.5 0.3 0.9 0.01 LPS 147 54 26 67 1.2 0.9 1.6 0.14 0.7 0.5 1.0 0.03 1.4 1.0 1.9 0.04 0.9 0.6 1.4 0.71
PEPG 147 53 26 67 0.7 0.6 0.8 0.00 0.7 0.5 0.9 0.01 0.8 0.6 1.0 0.03 0.5 0.4 0.7 0.00 PEPG 147 53 26 67 1.0 0.8 1.2 0.89 0.6 0.5 0.8 0.00 1.1 0.9 1.4 0.20 0.7 0.6 1.0 0.03
Pam3 128 49 21 58 1.0 0.8 1.3 0.96 0.9 0.6 1.2 0.45 1.0 0.8 1.4 0.75 0.9 0.7 1.3 0.65 Pam3 128 49 21 58 1.0 0.8 1.4 0.74 0.9 0.6 1.3 0.51 1.1 0.8 1.5 0.57 1.0 0.7 1.3 0.78
R848 150 57 27 66 0.7 0.5 1.0 0.03 0.6 0.4 0.9 0.01 0.9 0.6 1.2 0.39 0.5 0.3 0.7 0.00 R848 150 57 27 66 0.8 0.5 1.3 0.42 0.7 0.4 1.4 0.30 0.9 0.5 1.6 0.77 0.7 0.3 1.2 0.18
SA 98 36 16 46 0.8 0.7 1.1 0.14 0.8 0.6 1.1 0.11 0.9 0.7 1.2 0.40 0.7 0.5 1.0 0.08 SA 98 36 16 46 0.9 0.6 1.3 0.49 0.9 0.5 1.6 0.79 0.9 0.6 1.3 0.54 0.8 0.5 1.5 0.54
SP 74 27 13 34 0.8 0.6 1.0 0.07 0.8 0.5 1.1 0.20 0.9 0.6 1.1 0.26 0.7 0.5 1.0 0.03 SP 74 27 13 34 1.0 0.7 1.3 0.94 0.8 0.5 1.2 0.30 1.1 0.8 1.5 0.67 0.8 0.5 1.3 0.44
GBS 113 43 19 51 0.9 0.8 1.2 0.57 0.7 0.5 0.9 0.01 1.1 0.8 1.3 0.62 0.7 0.5 1.0 0.02 GBS 113 43 19 51 1.1 0.9 1.5 0.34 0.7 0.5 1.1 0.12 1.2 0.9 1.7 0.15 0.9 0.6 1.4 0.73
EC 157 62 28 67 0.8 0.6 1.0 0.05 0.7 0.5 0.9 0.01 0.9 0.7 1.2 0.45 0.6 0.4 0.8 0.00 EC 157 62 28 67 1.0 0.9 1.2 0.71 0.8 0.6 1.0 0.02 1.1 0.9 1.3 0.27 0.9 0.7 1.1 0.19
HI 141 56 22 63 0.9 0.7 1.1 0.25 0.6 0.4 0.9 0.01 1.0 0.7 1.3 0.95 0.6 0.4 0.9 0.00 HI 141 56 22 63 1.0 0.8 1.2 0.83 0.8 0.6 1.0 0.07 1.1 0.9 1.3 0.64 0.8 0.6 1.1 0.11
LM 69 23 12 33 0.7 0.5 1.0 0.03 1.0 0.7 1.5 0.99 0.7 0.5 1.0 0.07 0.7 0.5 1.1 0.11 LM 69 23 12 33 0.9 0.6 1.2 0.41 1.4 0.9 2.2 0.18 0.8 0.6 1.1 0.17 1.0 0.6 1.7 0.88
CA 86 32 15 39 0.8 0.5 1.2 0.28 0.8 0.4 1.3 0.34 0.9 0.6 1.4 0.54 0.7 0.4 1.1 0.14 CA 86 32 15 39 0.8 0.5 1.4 0.52 0.8 0.4 1.7 0.53 0.9 0.5 1.6 0.78 0.7 0.4 1.4 0.30
MCP-1 BCG 129 51 19 59 1.0 0.8 1.3 0.98 0.7 0.5 1.1 0.11 1.1 0.8 1.4 0.52 0.8 0.6 1.2 0.25 IFN-γ BCG 129 51 19 59 1.9 0.9 4.0 0.10 1.1 0.3 3.9 0.83 1.9 0.8 4.2 0.12 2.0 0.6 6.1 0.23
MTBK 98 37 17 44 1.0 0.8 1.4 0.82 0.8 0.5 1.2 0.28 1.1 0.8 1.5 0.56 0.9 0.6 1.4 0.62 MTBK 98 37 17 44 1.5 0.8 2.7 0.16 1.7 0.8 3.7 0.15 1.2 0.7 2.3 0.52 2.3 0.9 5.6 0.07
LPS 147 54 26 67 0.9 0.6 1.3 0.45 0.7 0.4 1.0 0.06 1.0 0.7 1.5 1.00 0.7 0.4 1.1 0.13 LPS 147 54 26 67 1.2 0.6 2.6 0.56 0.4 0.1 1.1 0.07 1.6 0.7 3.7 0.25 0.7 0.3 1.9 0.53
PEPG 147 53 26 67 0.8 0.6 1.0 0.04 0.8 0.5 1.1 0.12 0.9 0.7 1.1 0.25 0.7 0.5 0.9 0.01 PEPG 147 53 26 67 0.7 0.3 1.4 0.33 0.9 0.3 2.5 0.83 0.7 0.3 1.6 0.43 0.7 0.2 1.9 0.46
Pam3 128 49 21 58 0.9 0.7 1.1 0.36 0.9 0.6 1.2 0.37 0.9 0.7 1.2 0.63 0.8 0.6 1.1 0.21 Pam3 128 49 21 58 1.2 0.7 2.0 0.51 1.3 0.6 2.8 0.45 1.1 0.6 1.9 0.76 1.5 0.7 3.1 0.28
R848 150 57 27 66 0.8 0.7 1.0 0.01 0.8 0.6 1.0 0.05 0.9 0.7 1.0 0.16 0.7 0.5 0.8 0.00 R848 150 57 27 66 0.8 0.3 1.8 0.52 0.5 0.1 1.7 0.27 0.9 0.4 2.5 0.89 0.5 0.2 1.7 0.28
SA 98 36 16 46 0.8 0.6 1.1 0.20 0.8 0.5 1.2 0.27 0.9 0.6 1.2 0.43 0.7 0.5 1.1 0.15 SA 98 36 16 46 0.8 0.3 1.9 0.56 2.5 0.7 9.3 0.18 0.6 0.2 1.6 0.28 1.4 0.4 5.1 0.59
SP 74 27 13 34 0.7 0.5 0.9 0.01 0.7 0.4 1.1 0.11 0.7 0.5 1.0 0.05 0.5 0.3 0.8 0.00 SP 74 27 13 34 1.0 0.4 2.5 0.95 0.3 0.1 1.0 0.06 1.5 0.6 3.9 0.37 0.4 0.1 1.7 0.23
GBS 113 43 19 51 0.9 0.7 1.1 0.28 0.7 0.5 1.1 0.09 1.0 0.7 1.2 0.75 0.7 0.5 1.0 0.06 GBS 113 43 19 51 1.3 0.6 3.2 0.50 0.6 0.2 1.9 0.37 1.6 0.6 4.1 0.34 0.9 0.3 3.5 0.92
EC 157 62 28 67 0.8 0.6 1.0 0.03 0.7 0.5 1.0 0.06 0.9 0.7 1.1 0.21 0.6 0.5 0.9 0.00 EC 157 62 28 67 1.2 0.7 2.3 0.51 1.3 0.6 3.3 0.50 1.1 0.5 2.3 0.76 1.6 0.7 4.0 0.29
HI 141 56 22 63 0.8 0.7 1.0 0.07 0.8 0.6 1.2 0.30 0.9 0.7 1.1 0.22 0.7 0.6 1.0 0.03 HI 141 56 22 63 1.6 0.8 3.1 0.19 1.3 0.5 3.6 0.64 1.5 0.7 3.1 0.32 1.8 0.7 4.9 0.22
LM 69 23 12 33 0.7 0.5 0.9 0.01 0.8 0.5 1.2 0.29 0.7 0.5 1.0 0.06 0.6 0.4 0.9 0.01 LM 69 23 12 33 1.4 0.5 3.7 0.47 0.6 0.2 2.4 0.49 1.7 0.6 5.1 0.34 1.1 0.3 3.9 0.93
CA 86 32 15 39 0.6 0.4 0.9 0.01 0.9 0.5 1.6 0.65 0.6 0.4 0.9 0.02 0.6 0.4 0.9 0.02 CA 86 32 15 39 0.8 0.4 1.6 0.47 0.5 0.2 1.4 0.19 0.9 0.4 2.1 0.88 0.5 0.2 1.4 0.18
Late	v	controls
95%CI95%CI 95%CI 95%CI
Early	v	Late Early	v	controls
95%CI
Late	v	controls BCGBCG Early	v	Late Early	v	controls
95%CI 95%CI 95%CI
Table	2:	Univariate	analysis	of	the	effect	of	BCG	vaccination based	on	timing	of	randomisation.	Early	BCG	=	randomised	<	48	hours	of	life,	Late	BCG	vaccine	=	randomisation	>	48	hours	of	life	on	neonatal	cytokine	profiles	in	
response	to	toll	like	receptor	ligands	and	a	selection	of	mycobacterial	and	heterologous	"non-specific"	antigens.	Total	(n)	refers	to	the	number	of	stimulations	included	in	the	analysis.		The	%	within	the	detectable	limits	of	the	
assay	is	also	provided.	GMR=	Geometric	Means	Ratio.	Staistically	significant	values	are	depicted	in	red.	GMR	>1.0	indicates	the	effect	was	stronger	in	BCG	vaccinated	subjects,	subjects	of	the	male	sex	and	those	born	by	LSCS.	
BCG=	Bacille	Calmette	Guerin,	MTBK=	Killed	Mycobacterium	Tuberculosis,	LPS	=	Lipopolysaccharide,	PEPG	=	peptidoglycan,	PamCys3=(S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-
Lys4OH,trihydrochloride,	R848=	resiquimod,	GBS=	Group	B	Streptococcus,	GAS=	Group	A	streptococcus.
 
Supplementary Table 4 
 
 
Dataset	1
Cytokine Stimulant DS1	(n) GMR p	value DS2	(n) GMR p	value DS3	(n) GMR p	value Cytokine Stimulant DS1	(n) GMR p	value DS2(n) GMR p	value DS3(n) GMR p	value
LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI LCI UCI
IL-1ra BCG 129 1.1 0.7 1.7 0.62 123 1.3 0.8 2.1 0.26 121 1.0 0.8 1.4 0.72 IL-8 BCG 129 1.0 0.9 1.3 0.70 129 1.0 0.9 1.3 0.70 129 1.0 0.9 1.3 0.70
MTBK 98 1.0 0.7 1.6 0.85 96 1.2 0.8 2.0 0.39 94 1.4 1.0 1.9 0.06 MTBK 98 1.2 0.9 1.7 0.27 98 1.2 0.9 1.8 0.24 98 1.2 0.9 1.8 0.24
LPS 147 0.8 0.6 1.3 0.40 138 0.9 0.6 1.5 0.75 137 0.9 0.7 1.1 0.22 LPS 147 1.0 0.8 1.3 0.94 147 1.0 0.7 1.4 0.96 147 1.0 0.7 1.4 0.90
PEPG 146 0.9 0.7 1.2 0.46 145 1.0 0.7 1.3 0.79 144 0.9 0.7 1.1 0.19 PEPG 146 0.9 0.7 1.1 0.37 146 0.9 0.7 1.1 0.40 142 0.9 0.7 1.1 0.39
Pam3 128 0.8 0.6 1.2 0.32 121 0.9 0.6 1.4 0.73 117 1.0 0.8 1.3 0.89 Pam3 128 1.1 0.8 1.5 0.68 128 1.0 0.7 1.5 0.89 127 1.1 0.8 1.7 0.48
R848 150 0.8 0.6 1.0 0.06 149 0.8 0.6 1.0 0.11 149 0.8 0.6 0.9 0.01 R848 150 0.9 0.7 1.2 0.70 150 1.0 0.7 1.3 0.77 150 1.0 0.7 1.3 0.85
SA 98 0.8 0.5 1.2 0.19 92 0.8 0.5 1.4 0.47 91 0.9 0.7 1.2 0.35 SA 98 0.9 0.7 1.3 0.67 98 0.9 0.7 1.3 0.70 98 0.9 0.7 1.3 0.70
SP 74 0.7 0.5 1.1 0.09 72 0.8 0.5 1.3 0.39 72 0.8 0.6 1.1 0.15 SP 74 0.8 0.7 1.1 0.17 74 0.9 0.7 1.2 0.64 74 0.9 0.7 1.2 0.64
GBS 113 0.9 0.6 1.2 0.37 110 0.9 0.6 1.4 0.71 108 0.9 0.7 1.2 0.40 GBS 113 1.0 0.8 1.3 0.95 113 1.0 0.8 1.3 0.95 113 1.0 0.8 1.3 0.95
EC 157 0.8 0.6 1.1 0.13 155 0.9 0.7 1.2 0.41 154 0.9 0.7 1.1 0.17 EC 157 1.0 0.8 1.2 0.81 157 1.1 0.8 1.4 0.58 157 1.1 0.8 1.4 0.56
HI 141 0.8 0.6 1.1 0.25 137 0.9 0.6 1.3 0.56 136 0.9 0.7 1.1 0.43 HI 141 1.0 0.8 1.2 0.92 141 1.0 0.8 1.3 0.99 141 1.0 0.8 1.3 0.97
LM 69 0.5 0.3 0.9 0.01 63 0.6 0.3 1.2 0.16 62 0.7 0.5 1.0 0.04 LM 69 0.7 0.5 1.1 0.11 69 0.8 0.5 1.3 0.48 69 0.8 0.5 1.3 0.48
CA 86 0.7 0.4 1.1 0.10 76 0.8 0.4 1.6 0.56 73 1.0 0.7 1.3 0.79 CA 86 0.8 0.5 1.1 0.15 86 0.8 0.5 1.2 0.24 85 0.8 0.5 1.3 0.36
IL-10 BCG 129 1.0 0.7 1.3 0.77 128 0.9 0.7 1.3 0.72 127 0.8 0.6 1.1 0.12 MIF BCG 129 0.9 0.8 1.0 0.06 129 0.9 0.7 1.0 0.06 129 0.9 0.7 1.0 0.06
MTBK 98 1.3 0.7 2.5 0.44 93 1.3 0.7 2.5 0.44 89 0.9 0.6 1.3 0.63 MTBK 98 0.9 0.8 1.0 0.09 98 0.9 0.7 1.0 0.11 98 0.9 0.7 1.0 0.11
LPS 147 1.1 0.7 1.9 0.62 143 1.1 0.7 1.8 0.67 141 0.9 0.7 1.3 0.72 LPS 147 1.0 0.9 1.1 0.81 147 1.0 0.8 1.2 0.87 147 1.0 0.8 1.2 0.88
PEPG 146 0.8 0.7 1.0 0.09 147 0.8 0.7 1.0 0.07 145 0.8 0.7 1.0 0.08 PEPG 146 1.0 0.9 1.1 0.42 146 1.0 0.8 1.1 0.66 146 1.0 0.8 1.1 0.66
Pam3 128 0.8 0.5 1.4 0.49 128 0.8 0.5 1.3 0.41 100 0.9 0.6 1.2 0.40 Pam3 128 0.9 0.8 1.1 0.29 128 0.9 0.7 1.2 0.39 128 1.0 0.8 1.2 0.93
R848 150 0.7 0.6 1.0 0.02 150 0.7 0.6 0.9 0.02 150 0.7 0.6 1.0 0.02 R848 150 1.0 0.9 1.0 0.28 150 1.0 0.8 1.2 0.74 150 1.0 0.8 1.2 0.80
SA 98 0.9 0.6 1.3 0.61 98 0.9 0.6 1.3 0.56 93 0.9 0.7 1.2 0.40 SA 98 1.0 0.9 1.1 0.76 98 1.0 0.8 1.3 0.70 98 1.0 0.8 1.3 0.70
SP 74 1.1 0.8 1.5 0.62 74 1.1 0.8 1.5 0.60 74 1.1 0.8 1.5 0.60 SP 74 1.0 0.9 1.1 0.72 74 1.1 0.9 1.3 0.60 74 1.1 0.9 1.3 0.60
GBS 113 1.2 0.9 1.6 0.18 113 1.2 0.9 1.6 0.24 113 1.2 0.9 1.6 0.24 GBS 113 1.1 0.9 1.2 0.32 113 1.1 0.9 1.3 0.43 113 1.1 0.9 1.3 0.43
EC 157 0.9 0.7 1.1 0.23 157 0.9 0.7 1.1 0.18 157 0.9 0.7 1.1 0.26 EC 157 1.1 1.0 1.1 0.25 157 1.1 0.9 1.3 0.39 157 1.1 0.9 1.3 0.36
HI 141 0.9 0.7 1.1 0.31 141 0.9 0.7 1.1 0.24 141 0.9 0.7 1.1 0.21 HI 141 1.0 0.9 1.1 0.56 141 1.0 0.8 1.2 0.95 141 1.0 0.8 1.2 0.94
LM 69 0.9 0.6 1.3 0.47 69 0.9 0.6 1.3 0.47 57 0.8 0.5 1.2 0.24 LM 69 0.9 0.8 1.0 0.07 69 1.0 0.8 1.3 0.94 69 1.0 0.8 1.3 0.94
CA 86 1.2 0.5 2.9 0.64 71 1.2 0.5 2.7 0.73 55 1.1 0.7 1.8 0.71 CA 86 1.0 0.9 1.1 0.88 86 1.0 0.8 1.3 0.74 86 1.0 0.8 1.3 0.74
MIG BCG 129 0.9 0.8 1.0 0.14 129 0.8 0.7 1.1 0.15 126 0.8 0.6 1.0 0.04 IL-1β BCG 129 0.9 0.8 1.1 0.38 129 0.9 0.8 1.1 0.39 128 0.9 0.8 1.1 0.34
MTBK 98 0.8 0.7 1.0 0.06 98 0.8 0.6 1.1 0.23 95 0.9 0.6 1.1 0.25 MTBK 98 1.1 0.6 1.8 0.76 98 1.1 0.6 1.8 0.81 97 1.1 0.6 1.9 0.75
LPS 147 1.1 0.9 1.3 0.50 147 0.9 0.7 1.2 0.63 146 1.0 0.8 1.2 0.79 LPS 147 0.9 0.6 1.3 0.46 147 0.9 0.6 1.4 0.68 145 0.9 0.6 1.3 0.67
PEPG 146 0.9 0.7 1.1 0.17 146 0.8 0.6 1.0 0.05 146 0.8 0.6 1.0 0.05 PEPG 146 0.9 0.7 1.1 0.27 146 0.9 0.7 1.2 0.39 144 0.9 0.7 1.1 0.29
Pam3 128 1.0 0.9 1.1 0.81 127 0.9 0.7 1.1 0.17 126 0.9 0.8 1.2 0.65 Pam3 128 1.0 0.7 1.4 0.91 128 1.0 0.7 1.5 0.95 117 1.1 0.8 1.6 0.54
R848 150 0.9 0.7 1.3 0.70 150 0.9 0.6 1.2 0.43 150 0.9 0.7 1.2 0.47 R848 150 0.8 0.6 1.2 0.30 150 0.9 0.6 1.2 0.43 150 0.9 0.6 1.2 0.40
SA 98 1.0 0.8 1.2 0.99 98 0.9 0.7 1.2 0.50 98 0.9 0.7 1.2 0.50 SA 98 0.8 0.5 1.1 0.16 98 0.8 0.5 1.1 0.16 95 0.9 0.6 1.2 0.41
SP 74 1.1 0.8 1.4 0.71 74 1.0 0.7 1.5 0.84 74 1.0 0.7 1.5 0.84 SP 74 1.0 0.7 1.4 0.98 74 1.0 0.7 1.4 0.90 74 1.0 0.7 1.4 0.90
GBS 113 1.1 0.8 1.4 0.63 113 1.0 0.7 1.3 0.83 113 1.0 0.7 1.3 0.83 GBS 113 1.0 0.7 1.3 0.75 113 1.0 0.7 1.3 0.83 109 0.9 0.7 1.3 0.69
EC 157 1.0 0.9 1.1 0.94 157 0.9 0.7 1.1 0.18 157 0.9 0.7 1.1 0.34 EC 157 1.1 0.8 1.4 0.68 157 1.1 0.9 1.4 0.44 150 1.0 0.8 1.4 0.80
HI 141 0.9 0.8 1.1 0.45 141 0.8 0.7 1.0 0.09 141 0.8 0.7 1.0 0.10 HI 141 0.9 0.7 1.2 0.63 141 1.0 0.7 1.3 0.81 136 1.0 0.7 1.3 0.74
LM 69 0.9 0.7 1.1 0.19 69 0.8 0.6 1.2 0.31 69 0.8 0.6 1.2 0.31 LM 69 0.9 0.6 1.2 0.40 69 0.9 0.6 1.3 0.45 69 0.9 0.6 1.3 0.45
CA 86 0.9 0.8 1.1 0.34 86 0.8 0.6 1.1 0.24 85 0.9 0.7 1.1 0.31 CA 86 0.8 0.4 1.5 0.48 86 0.8 0.4 1.5 0.49 81 0.8 0.5 1.3 0.42
MIP-1α BCG 129 0.9 0.7 1.1 0.28 129 0.9 0.7 1.1 0.29 118 0.9 0.7 1.1 0.31 IL-6 BCG 129 1.0 0.8 1.2 0.77 129 1.0 0.8 1.2 0.97 129 1.0 0.8 1.2 0.97
MTBK 98 1.1 0.6 1.9 0.76 98 1.1 0.6 1.9 0.70 96 1.2 0.7 2.1 0.44 MTBK 98 1.1 0.6 1.8 0.74 98 1.1 0.7 1.9 0.63 98 1.1 0.7 1.9 0.63
LPS 147 0.9 0.6 1.4 0.75 147 1.0 0.6 1.5 0.86 135 1.1 0.7 1.7 0.65 LPS 147 0.9 0.7 1.3 0.66 147 1.0 0.7 1.3 0.97 147 1.0 0.7 1.4 0.96
PEPG 146 0.7 0.5 0.9 0.01 147 0.7 0.5 0.9 0.01 124 0.8 0.6 1.0 0.06 PEPG 146 0.8 0.6 1.0 0.02 146 0.8 0.7 1.0 0.04 147 0.8 0.7 1.0 0.04
Pam3 128 1.2 0.7 2.1 0.57 128 1.2 0.7 2.1 0.57 127 1.2 0.7 2.2 0.44 Pam3 128 0.9 0.5 1.6 0.80 126 1.0 0.6 1.8 0.96 126 1.0 0.6 1.6 0.98
R848 150 0.7 0.5 1.0 0.06 150 0.8 0.6 1.1 0.13 126 0.8 0.6 1.1 0.13 R848 150 0.7 0.6 0.9 0.01 150 0.8 0.6 1.0 0.03 150 0.8 0.6 1.0 0.05
SA 98 0.7 0.4 1.1 0.15 98 0.7 0.4 1.1 0.15 96 0.7 0.4 1.0 0.05 SA 98 0.7 0.4 1.1 0.09 98 0.7 0.4 1.1 0.12 98 0.7 0.4 1.1 0.12
SP 74 0.8 0.6 1.2 0.27 74 0.8 0.6 1.2 0.28 71 0.9 0.7 1.2 0.49 SP 74 0.9 0.7 1.3 0.73 74 1.0 0.7 1.4 0.80 74 1.0 0.7 1.4 0.80
GBS 113 1.1 0.7 1.6 0.73 113 1.1 0.7 1.6 0.65 111 1.1 0.8 1.6 0.63 GBS 113 0.9 0.7 1.3 0.69 113 1.0 0.7 1.4 0.91 113 1.0 0.7 1.4 0.91
EC 157 0.9 0.7 1.2 0.50 157 0.9 0.7 1.2 0.48 143 0.9 0.7 1.2 0.61 EC 157 0.9 0.7 1.1 0.22 157 0.9 0.7 1.1 0.38 157 0.9 0.7 1.1 0.40
HI 141 0.9 0.6 1.1 0.25 141 0.9 0.6 1.1 0.24 113 0.9 0.7 1.2 0.50 HI 141 0.8 0.6 1.1 0.14 141 0.9 0.7 1.1 0.25 141 0.9 0.7 1.1 0.25
LM 69 0.8 0.4 1.4 0.38 69 0.8 0.4 1.4 0.39 69 0.8 0.4 1.4 0.39 LM 69 0.7 0.4 1.2 0.17 69 0.7 0.4 1.3 0.27 69 0.7 0.4 1.3 0.27
CA 86 0.7 0.3 1.5 0.38 86 0.7 0.3 1.5 0.36 85 0.8 0.4 1.6 0.53 CA 86 0.6 0.3 1.5 0.26 84 0.6 0.2 1.5 0.29 86 0.9 0.5 1.7 0.73
MIP-1β BCG 129 0.9 0.7 1.1 0.23 129 0.9 0.7 1.1 0.23 114 0.9 0.8 1.1 0.28 TNF-α BCG 129 0.9 0.7 1.1 0.35 129 0.9 0.7 1.1 0.37 129 0.9 0.7 1.1 0.37
MTBK 98 1.1 0.8 1.4 0.55 98 1.1 0.8 1.4 0.54 94 1.1 0.8 1.4 0.69 MTBK 98 0.9 0.6 1.4 0.67 98 0.9 0.6 1.4 0.69 98 0.9 0.6 1.4 0.69
LPS 147 0.8 0.5 1.1 0.14 147 0.7 0.5 1.1 0.11 100 0.9 0.5 1.4 0.52 LPS 147 1.2 0.9 1.6 0.14 147 1.2 0.9 1.6 0.31 147 1.2 0.9 1.6 0.26
PEPG 146 0.7 0.6 0.8 0.00 147 0.7 0.6 0.8 0.00 120 0.8 0.6 0.9 0.01 PEPG 146 1.0 0.8 1.2 0.89 146 1.0 0.8 1.2 0.64 145 1.0 0.8 1.2 0.67
Pam3 128 1.0 0.8 1.3 0.96 128 1.0 0.7 1.3 0.81 127 1.0 0.7 1.3 0.84 Pam3 128 1.0 0.8 1.4 0.74 127 1.0 0.7 1.3 0.89 127 1.0 0.8 1.4 0.78
R848 150 0.7 0.5 1.0 0.03 150 0.7 0.5 1.0 0.02 95 0.8 0.6 1.1 0.10 R848 150 0.8 0.5 1.3 0.42 150 0.8 0.5 1.3 0.30 120 0.9 0.5 1.4 0.52
SA 98 0.8 0.7 1.1 0.14 98 0.8 0.6 1.0 0.08 98 0.8 0.6 1.0 0.08 SA 98 0.9 0.6 1.3 0.49 98 0.8 0.6 1.2 0.37 98 0.8 0.6 1.2 0.37
SP 74 0.8 0.6 1.0 0.07 74 0.8 0.6 1.0 0.11 68 0.9 0.7 1.1 0.19 SP 74 1.0 0.7 1.3 0.94 74 1.0 0.7 1.4 0.92 74 1.0 0.7 1.4 0.92
GBS 113 0.9 0.8 1.2 0.57 113 0.9 0.7 1.1 0.42 109 0.9 0.8 1.2 0.62 GBS 113 1.1 0.9 1.5 0.34 113 1.1 0.8 1.5 0.64 113 1.1 0.8 1.5 0.64
EC 157 0.8 0.6 1.0 0.05 157 0.8 0.6 1.0 0.06 93 1.0 0.7 1.3 0.72 EC 157 1.0 0.9 1.2 0.71 157 1.0 0.8 1.2 0.95 156 1.0 0.8 1.2 0.89
HI 141 0.9 0.7 1.1 0.25 141 0.8 0.6 1.1 0.21 101 0.9 0.7 1.1 0.25 HI 141 1.0 0.8 1.2 0.83 141 0.9 0.7 1.2 0.50 141 0.9 0.7 1.2 0.52
LM 69 0.7 0.5 1.0 0.03 69 0.7 0.5 1.0 0.07 69 0.7 0.5 1.0 0.07 LM 69 0.9 0.6 1.2 0.41 69 0.9 0.6 1.3 0.54 69 0.9 0.6 1.3 0.54
CA 86 0.8 0.5 1.2 0.28 86 0.8 0.5 1.2 0.19 86 0.8 0.5 1.2 0.19 CA 86 0.8 0.5 1.4 0.52 86 0.8 0.5 1.4 0.40 86 0.8 0.5 1.4 0.40
MCP-1 BCG 129 1.0 0.8 1.3 0.98 129 1.0 0.8 1.3 0.96 129 1.0 0.8 1.3 0.96 IFN-γ BCG 129 1.9 0.9 4.0 0.10 66 1.8 0.8 4.0 0.12 26 1.0 0.5 2.0 0.99
MTBK 98 1.0 0.8 1.4 0.82 98 1.1 0.8 1.4 0.67 98 1.1 0.8 1.4 0.67 MTBK 98 1.5 0.8 2.7 0.16 28 1.4 0.7 2.6 0.32 7 0.1 0.0 0.7 0.02
LPS 146 0.9 0.6 1.3 0.45 147 0.9 0.6 1.3 0.53 147 0.9 0.6 1.3 0.52 LPS 147 1.2 0.6 2.6 0.56 78 1.4 0.7 3.1 0.37 44 0.8 0.5 1.4 0.52
PEPG 147 0.8 0.6 1.0 0.04 147 0.8 0.6 1.0 0.04 146 0.8 0.7 1.0 0.07 PEPG 146 0.7 0.3 1.4 0.33 117 0.8 0.4 1.5 0.43 88 0.7 0.5 1.0 0.04
Pam3 128 0.9 0.7 1.1 0.36 128 0.9 0.7 1.2 0.46 127 1.0 0.7 1.2 0.77 Pam3 128 1.2 0.7 2.0 0.51 40 1.4 0.8 2.4 0.29 10 0.6 0.1 2.5 0.40
R848 150 0.8 0.7 1.0 0.01 150 0.8 0.7 1.0 0.02 147 0.8 0.7 1.0 0.05 R848 150 0.8 0.3 1.8 0.52 139 0.8 0.3 1.9 0.61 133 0.8 0.5 1.3 0.36
SA 98 0.8 0.6 1.1 0.20 98 0.9 0.6 1.2 0.39 97 0.9 0.6 1.2 0.33 SA 98 0.8 0.3 1.9 0.56 50 0.8 0.3 2.1 0.66 26 1.2 0.7 2.1 0.46
SP 74 0.7 0.5 0.9 0.01 74 0.7 0.5 1.0 0.04 73 0.7 0.5 0.9 0.02 SP 74 1.0 0.4 2.5 0.95 65 1.0 0.4 2.5 0.93 44 1.0 0.7 1.6 0.86
GBS 113 0.9 0.7 1.1 0.28 113 0.9 0.7 1.1 0.35 113 0.9 0.7 1.1 0.35 GBS 113 1.3 0.6 3.2 0.50 75 1.6 0.6 3.8 0.32 46 0.5 0.3 1.0 0.04
EC 157 0.8 0.6 1.0 0.03 157 0.8 0.6 1.0 0.04 157 0.8 0.7 1.0 0.06 EC 157 1.2 0.7 2.3 0.51 92 1.4 0.7 2.9 0.29 47 0.7 0.4 1.2 0.19
HI 141 0.8 0.7 1.0 0.07 141 0.8 0.7 1.0 0.08 141 0.8 0.7 1.0 0.07 HI 141 1.6 0.8 3.1 0.19 73 1.8 0.9 3.7 0.12 32 1.0 0.5 2.0 0.91
LM 69 0.7 0.5 0.9 0.01 69 0.8 0.6 1.1 0.15 69 0.8 0.6 1.1 0.15 LM 69 1.4 0.5 3.7 0.47 32 1.6 0.6 4.3 0.38 11 0.6 0.3 1.4 0.22
CA 86 0.6 0.4 0.9 0.01 86 0.7 0.4 1.0 0.06 86 0.7 0.4 1.0 0.06 CA 86 0.8 0.4 1.6 0.47 26 0.8 0.4 1.7 0.56 5 0.2 0.1 1.2 0.06
95%CI 95%CI
Dataset	1 Dataset	2 Dataset	3
95%CI
Dataset	2 Dataset	3
95%CI 95%CI 95%CI
Table	3:	Sensitivity analyses	for	the	effect	of	BCG	vaccination.	Dataset	1=	Complete	dataset.	Dataset	2=	Complete	dataset	following	removal	of	values	assigned	at	the	lower	limit	of	detection.	Dataset	3=	Complete	
dataset	following	removal	of	values	assigned	at	the	lower	limit	of	detection	and	values	extrapolated	by	the	Luminex	Xmap	software	at	both	the	upper	and	lower	ends	of	the	curve.	Total	(n)	refers	to	the	number	
of	stimulations	included	in	the	analysis.	GMR=	Geometric	Means	Ratio.	Staistically	significant	values	(p<0.05)	are	depicted	in	red,	those	approaching	significance	(p<0.07)	are	shown	in	orange	to	illustrate	where	
trends	are	maintained.	GMR	>1.0	indicates	the	effect	was	stronger	in	BCG	vaccinated	subjects.	BCG=	Bacille	Calmette	Guerin,	MTBK=	Killed	Mycobacterium	Tuberculosis,	LPS	=	Lipopolysaccharide,	PEPG	=	
peptidoglycan,	PamCys3=(S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4OH,trihydrochloride,	R848=	resiquimod,	SA=	S.	aureus,	SP=	S.	pneumoniae,	GBS=	Group	B	Streptococcus,	EC=	
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Supplementary data Table 2: Univariate analysis of the effect of BCG vaccination and 
maternal BCG vaccination on neonatal cytokine response to toll like receptor ligands and a 
selection of heterologous antigens. Total (n) refers to the number of stimulations included 
in the analysis. GMR= Geometric Means Ratio. Staistically significant values (p<0.05) are 
depicted in red. GMR >1.0 indicates the effect was stronger in BCG vaccinated subjects and 
infants whose mothers’ were BCG-vaccinated. BCG= Bacille Calmette Guerin, MTBK= Killed 
Mycobacterium Tuberculosis, LPS = Lipopolysaccharide, PEPG = peptidoglycan, 
PamCys3=(S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-
Lys4OH,trihydrochloride, R848= resiquimod, SA= S. aureus, SP= S. pneumoniae, GBS= Group 
B Streptococcus, EC= E.coli, HI= H. influenzae, LM= L. monocytogenes, CA= C. albicans. 
 
Supplementary data Table 3: Interaction analyses looking for a differential effect on 
cytokine expression following BCG vaccination between (i) boys and girls (ii) infants born 
by vaginal delivery compared with infants born by Cesarean section (iii) infants whose 
mothers are BCG vaccinated compared with infants whose mothers are non BCG 
vaccinated.  Total (n) refers to the number of stimulations included in the analysis.   GMR= 
Geometric Means Ratio. Statistically significant values are depicted in red (p<=0.05) and 
those approaching significance p<=0.07 in orange). BCG= Bacille Calmette Guerin, MTBK= 
Killed Mycobacterium Tuberculosis, LPS = Lipopolysaccharide, PEPG = peptidoglycan, 
PamCys3=(S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-
Lys4OH,trihydrochloride, R848= resiquimod, SA= S .aureus, SP= S. pneumoniae, EC= E. coli, 
HI= H. influenzae, LM= L. monocytogenes, CA= C. albicans, GBS= Group B Streptococcus, 
GAS= Group A streptococcus. 
 
Supplementary Figure 2: Relationship between timing of randomisation (early BCG = 
randomisation < 48 hours, late BCG= randomisation >48 hours) and a) age at BCG 
vaccination, b) age at blood sample and c) time to blood sample.  
 
Supplementary data Table 4: Univariate analysis of the effect of BCG vaccination based on 
the timing of randomisation. Early BCG = randomised < 48 hours of life, Late BCG 
vaccination > 48 hours of life on neonatal cytokine response to toll like receptor ligands 
and a selection of heterologous antigens. BCG= Bacille Calmette Guerin, MTBK= Killed 
Mycobacterium Tuberculosis, LPS = Lipopolysaccharide, PEPG = peptidoglycan, 
PamCys3=(S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-
Lys4OH,trihydrochloride, R848= resiquimod, SA= S. aureus, SP= S. pneumoniae, GBS= Group 
B Streptococcus, EC= E.coli, HI= H. influenzae, LM= L. monocytogenes, CA= C. albicans. 
 
Supplementary data Table 5: Sensitivity analyses for the effect of BCG vaccination. 
Dataset 1= Complete dataset. Dataset 2= Complete dataset following removal of values 
assigned at the lower limit of detection. Dataset 3= Complete dataset following removal 
of values assigned at the lower limit of detection and values extrapolated by the Luminex 
Xmap software at both the upper and lower ends of the curve. Total (n) refers to the 
number of stimulations included in the analysis. GMR= Geometric Means Ratio. Staistically 
significant values (p<0.05) are depicted in red, those approaching significance (p<0.07) are 
shown in orange to illustrate where trends are maintained. GMR >1.0 indicates the effect 
was stronger in BCG vaccinated subjects.  
